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2. ABBREVIATIONS 
 
ALND       Axillary lymph node dissection 
AS              Angiosarcoma 
BCSS        Breast cancer specific survival 
BCT           Breast conserving therapy 
CT              Computed tomography 
DIEP        Deep inferior epigastric perforator 
DM            Distant metastasis 
ER             Oestrogen receptor  
HER-2     Human epidermal growth factor receptor-2 
IBR           Immediate breast reconstruction 
IBTR        Ipsilateral breast tumour recurrence 
IGAP        Inferior gluteal artery perforator  
IMF          Inframammary fold  
LD            Latissimus dorsi 
LR            Local recurrence 
LRR         Locoregional recurrence 
MRI         Magnetic resonance imaging 
NAC         Nipple-areolar complex 
OS            Overall survival 
PET         Positron emission tomography 
PgR         Progesterone receptor 
RT            Radiotherapy  
SGAP      Superior gluteal artery perforator  
SIEA       Superficial inferior epigastric artery 
SLNB      Sentinel lymph node biopsy 
SSM        Skin-sparing mastectomy 
TAP         Thoracodorsal artery perforator 
TFL         Tensor fascia lata 
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TMG        Transverse myocutaneous gracilis 
TRAM     Transverse rectus abdominis myocutaneous 
VRAM     Vertical rectus abdominis myocutaneous 
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3. ABSTRACT 
 
Background 
Local recurrence (LR) of breast cancer is defined as any recurrence of tumour in the ipsilateral 
thoracic wall and locoregional recurrence (LRR) as any recurrence in the ipsilateral thoracic wall or 
regional lymph nodes following surgery for primary breast cancer. Earlier consensus guidelines 
have stated that breast conservative therapy should aim to keep the LRR rate less than 15% at 10 
years and following mastectomy the LRR rate should be less than 10% at 10 years (Rutgers EJ. 
2001). Recent studies from our institution have reported a LR rate of 2.1% following beast 
conservative therapy with a median follow-up of 57 months (Siponen et al. 2011) and a LR rate of 
2.9% following mastectomy with a median follow-up of 89 months (Siponen et al. 2013). The 
standard of care for LRR has not been established but surgery forms a key part of most accepted 
strategies. The oncological safety of immediate breast reconstruction for primary breast cancer has 
been addressed in numerous studies but only a few have considered the oncological safety of 
delayed autologous breast reconstruction. It is important to remember that women treated for a 
primary breast cancer are at increased risk of developing a second new primary non-breast cancer. 
Radiotherapy-induced breast angiosarcoma is now increasingly being recognized in the medical 
literature and is an aggressive tumour with a poor prognosis.  
Patients and methods 
The first study consisted of 60 consecutive patients treated by skin sparing mastectomy and 
immediate breast reconstruction between 1995 and 2008 for an ipsilateral breast tumour 
recurrence. Study II consisted of 40 consecutively operated patients who were treated with wide 
soft tissue resection and immediate flap reconstruction for an extensive chest wall recurrent breast 
cancer between 1984 and 2011. In both studies I and II hospital records were analysed for surgical 
complications and oncological outcome with respect to local control and overall survival. Study III 
was based on 522 consecutive patients who underwent mastectomy with or without breast 
reconstruction between January 2000 and December 2003. Data on cancer recurrence and 
survival were collected from hospital records and the files of the Finnish Cancer Registry. Study IV 
consisted of 10 patients treated surgically between 1999 and 2010 for a breast angiosarcoma 
following earlier radiotherapy for primary breast cancer. Surgical notes and pathology reports were 
reviewed for macroscopic and microscopic resection margins. Data on recurrence and overall 
survival was obtained from surgical and oncological records.  
Results 
Study I 
60 patients underwent skin sparing mastectomy and immediate breast reconstruction for an 
ipsilateral breast tumour recurrence. The median follow-up time was 84 months. 11 (18%) patients 
developed disease relapse and consisted of 6 local re-recurrences (10%), 3 cases of regional lymph 
node metastasis and 2 cases of distant metastasis. 4 of the 11 (7% overall) patients with disease 
relapse eventually died. 5 year overall survival (OS) was 94% and 5 year disease-free survival (DFS) 
was 83%.  Nine (15%) cases that suffered a complication required reoperation. These consisted of 
one microvascular re-anastomosis, one case requiring debridement for wound infection, 4 cases of 
haematoma drainage and 3 cases of debridement with/without skin grafting for partial flap or fat 
necrosis. There were no complete flap losses. 
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Study II  
40 patients underwent wide soft tissue resection and immediate flap reconstruction for an 
extensive chest wall recurrent breast cancer. The median length of follow-up was 31 months. In 
patients treated with a curative intent tumour-free resection margins (R0) were achieved in 
24/31(77%) patients. The median DFS after extensive resection was 31 months and the median OS 
was 52 months. The 2 and 5 year OS rates were 71% and 32% respectively. In patients treated for 
symptom palliation clear microscopic margins (R0) were achieved in 3/9 patients. The median OS 
was 17 months. There were 2 LRRs and 1 relapse in the ipsilateral LD flap donor site. This was 
subsequently treated with radiotherapy. Multivariate cox regression analysis revealed that 
resection size was an independent prognostic factor with a threefold increased risk of mortality 
during follow-up for resections of more than 150 cm². There were 2 deaths (5%) at 30 days post-
operation due to medical complications and 2 re-operations (re-excision for non-radical resection 
and re-grafting of flap donor site). There were neither any complete nor partial flap losses. 
Study III 
522 consecutive patients underwent mastectomy with (n=131) or without (n=391) breast 
reconstruction. The median follow-up time was 102 months and the 8-year LRR rate was 5.4% 
(n=21) in the mastectomy only group, 0.8% (n=1) in the delayed reconstruction group and 23.1% 
(n=3) in the immediate reconstruction group. Cox multivariate analysis revealed immediate 
reconstruction to be an independent risk factor for LRR. However Cox multivariate analysis 
revealed no reconstruction to be an independent risk factor for distant metastasis (DM), poor 
breast cancer specific survival (BCSS) and poor overall survival (OS). 
Study IV  
10 patients underwent surgical resection for a breast angiosarcoma following earlier radiotherapy 
for primary breast cancer. Marked lateral macroscopic margins were at least 3 cm in 9/10 cases 
and clear histological margins were achieved in all cases. Defect coverage involved direct closure in 
2 cases, reconstruction with a pedicled latissimus dorsi flap in 4 cases and skin grafting in 4 cases. 
Median follow-up was 81 months and 3 patients suffered a recurrence. Two were local skin 
recurrences and the other was a distant skin recurrence to the contralateral breast. 5 year OS was 
70%. There were no complications.  
Conclusions 
Skin-sparing mastectomy and immediate breast reconstruction is a possible treatment option for 
selected patients who develop an ipsilateral breast tumour recurrence. In selected patients 
autologous flap reconstruction enables the resection of extensive chest wall recurrent breast 
tumours with acceptable morbidity and reasonable local control and survival. Palliative surgery can 
also be invaluable to improve the quality of life in patients with extensive symptomatic recurrences. 
In comparison to mastectomy only breast reconstruction does not appear to worsen the prognosis 
following treatment for primary breast cancer. Increased awareness of radiation-associated 
angiosarcoma, with no delay in diagnosis and ultimately excision with wide macroscopic margins, 
is vital in improving survival of this poorly known tumour. 
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4. INTRODUCTION 
 
Breast cancer has been studied from the very earliest days of surgery. In Hippocrates we read “A 
woman in Abdera had a carcinoma of the breast and bloody fluid ran from the nipple. When the 
discharge stopped she died”. Celsus, in the first century AD, recorded early attempts at surgery for 
this disease: “Some have used caustics, others the cautery, others cut them out with a 
knife…Notwithstanding they have returned and occasioned death”. We have travelled far since 
Celsus, Jean Louis Petit (1674-1750), Benjamin Bell (1749-1806), Joseph Pancoast (1805-1882), 
William Stewart Halsted (1852-1922) and others, but much still remains for us and our successors 
to achieve in the understanding of breast cancer (Ellis. 1986). 
In spite of huge advances in the past 20-30 years, the management of local recurrence of the 
disease is one such problem where a general consensus is still lacking. This is mostly due to its 
heterogeneous biological characteristics and lack of well-designed prospective clinical trials. 
Following breast conserving therapy the rate of local recurrence varies between 2 – 15% at 5 years 
(Kurtz et al. 1989; Veronesi et al. 1993; Fisher et al. 2002; Clarke et al. 2005). Approximately 5-10 
% of patients undergoing mastectomy for breast cancer may suffer a chest wall recurrence within 
10 years (Harris et al. 1996; Hsi et al. 1998; Buchanan et al. 2006; Elder et al. 2006; Siponen et al. 
2013). The appropriate management of a chest wall recurrence following mastectomy is even less 
clear due to the nature of the surgical challenge as well as the generally-held view that this subset of 
patients have a particularly poor prognosis.   
Reconstructive surgery is nowadays widely performed in the treatment of breast cancer. For some 
patients with a locally advanced primary tumour or a locally recurrent tumour reconstruction can 
enable an adequate resection to be carried out with the intention of cure. In other patients with 
more advanced recurrent disease and troublesome symptoms reconstruction can enhance the 
patient’s quality of life by providing palliation for bulky, necrotic tumours and allow social 
reintegration.  
Breast reconstruction is now a key part of comprehensive breast cancer treatment and presents 
several questions in relation to locally recurrent disease. Some studies have suggested that surgery 
may promote the growth of metastatic lesions (Tagliabue et al. 2003; Demicheli et al. 2008). Thus, 
could the extra surgery of a major reconstruction induce the reactivation of tumour cells? Is a late 
reconstruction for a long-time survivor of breast cancer safe for all patients and what kind of 
selection criteria should be considered? Could a reconstructed breast obscure the early diagnosis of 
a local relapse?  What is the appropriate treatment of a recurrence following reconstruction?  
A very rare but increasingly recognised condition is the development of angiosarcoma in the 
previously irradiated breast. This aggressive tumour is associated with high recurrence and poor 
survival and at present no standard management guidelines exist. 
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5. REVIEW OF THE LITERATURE 
 
5.1 Current management of primary breast cancer 
Incidence and Survival 
Between 2006 and 2010 there were on average 4144 new cases of breast cancer diagnosed in 
Finland per year and the age-adjusted incidence rate was 86.5 per 100,000. The 5 year survival 
rate for patients followed-up in 2007-2009 was 89% and this figure compares very favourably with 
other countries. There were 887 deaths due to breast cancer in 2010 (Finnish Cancer Registry 
2011). 
Primary surgery 
Breast conserving therapy (BCT) is defined as a partial mastectomy (breast conserving surgery) 
followed by whole breast irradiation. Numerous randomised trials with over 10 years follow-up 
have shown that BCT is equally efficacious as mastectomy for treating breast cancer. As BCT 
provides equivalent survival rates it has become the standard of care for women without 
contraindications to this approach (Fisher et al. 2002; Veronesi et al. 2002). In Helsinki the 
majority (50-60%) of patients with primary breast cancer are treated with breast-conserving 
surgery and radiotherapy.The standard resection is performed with the aim of achieving a lateral 
margin of at least 1 cm, including the underlying fascia as well as a strip of overlying skin (von 
Smitten. 2008). The addition of oncoplastic techniques has increased the possibilities of BCT 
(Meretoja et al. 2010). In Helsinki around 40% require mastectomy due to: tumour multifocality, 
large tumour in relation to breast size, insufficient histological resection margins following wide 
local excision (<5 mm), patient wishes, high-risk of recurrence (young patients, genetic 
predisposition or strong family history) and when radiotherapy is contraindicated or the patient 
non-compliant (Evidence-based medicine guidelines of diagnosis and treatment of breast cancer in 
Finland. 2007). The modern mastectomy, in contrast to the Halstedian approach, intends to leave 
as much of the normal anatomy as possible while removing all the breast tissue. The standard 
simple mastectomy excises the breast and skin envelope and leaves the pectoralis major muscle in 
place. A more recent modification of the simple mastectomy is the skin-sparing mastectomy (SSM). 
This aims to leave behind the breast skin envelope for reconstruction with either an implant or 
autologous tissue (Toth and Lappert. 1991; Rainsbury. 2006). From preservation of the skin, it has 
been a natural progression to consider preservation of the nipple. Nipple-sparing mastectomy 
(NSM) has become an acceptable option as a risk-reducing procedure but concerns still persist over 
its oncological safety and a general consensus has not yet been reached regarding its clinical 
application (Rusby et al. 2010). 
Axillary staging 
After primary tumour staging the next step in the staging of breast cancer is the assessment of the 
axillary nodal status. Lymph node metastases are the most significant prognostic indicator for 
patients who have breast cancer. Based on several trials and according to the American Society of 
Breast Surgeons, sentinel lymph node biopsy (SLNB) is the preferred method of axillary staging for 
patients with T1-3 invasive breast cancers that are clinically node negative, including 
multifocal/multicentric disease and prior breast surgery (The American Society of Breast Surgeons. 
2005). 
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Adjuvant therapy 
In Finland adjuvant chemo- and radiotherapy are administered according to national and 
international evidence-based guidelines (Finnish National Breast Cancer Treatment Guidelines. 
2007; National Comprehensive Cancer Network. NCCN guidelines®). The choice of systemic 
adjuvant treatment is based on tumour stage (tumour size, nodal status) and biological subtype of 
the tumour (estrogen and progesterone receptors, proliferation and HER2 gene expression) 
(Goldhirsch et al. 2011). 
Following breast conserving surgery post-operative radiotherapy consists of a total of 45-50 Gy 
(gray) for 5 weeks to the whole breast area. Premenopausal women and those with close margins 
receive a further 10 Gy boost to the tumour bed. Radiotherapy is also administered to the axillary 
area if there are four or more involved lymph nodes (N2a). Recent studies have shown that 
achieving local control through adequate surgery and inclusion of radiotherapy for patients with an 
invasive cancer treated with a lumpectomy not only decreases locoregional recurrence but also 
positively impacts on survival (Clarke et al. 2005). Radiotherapy is also administered following 
mastectomy to patients with tumours larger than 5cm, tumours infiltrating skin or pectoralis fascia 
or inflammatory tumours. 
It is widely accepted that all women under 35 years of age with invasive breast cancer or those with 
node-positive disease, ER-negative disease, HER-2 (human epidermal growth factor receptor-2) 
positivity or tumours larger than 1 cm should receive some form of chemotherapeutic regimen 
which usually consists of 6 cycles every 3 weeks. 
Five-year endocrine therapy is recommended for all women with ER-positive breast cancer greater 
than 1 cm in size, regardless of age, lymph node status, HER-2 status or menopausal status. In 
Helsinki premenopausal women receive tamoxifen and postmenopausal women either tamoxifen 
or an aromatase inhibitor for 5 years. 
HER-2 positive patients tend to have more aggressive disease and trastuzumab (Herceptin®, 
Genentech BioOncology), a recombinant, humanised IgG monoclonal antibody, is now 
recommended in combination with a chemotherapeutic regimen. 
 
5.2 Locally recurrent breast cancer 
Following surgery for primary breast cancer the disease may recur locally, regionally and/or at 
distant sites. Patients with a local relapse after primary breast cancer surgery tend to have a poor 
prognosis (Abner et al. 1993; Courdi A et al. 2006; Fodor et al. 2008). Breast cancer recurrence 
tends to occur in the first 5 years after treatment with a peak incidence after 2 years (Kimura et al. 
2007, Siponen et al. 2011). 
After BCT a local recurrence is defined as reappearance of cancer in the ipsilateral preserved 
breast.  Following mastectomy a local recurrence is defined as reappearance of cancer on the 
ipsilateral chest wall, usually close to the mastectomy scar.  In contrast, a regional recurrence 
denotes tumour involving the regional lymph nodes, usually ipsilateral axillary or supraclavicular, 
less commonly infraclavicular and/or internal mammary nodes. Local recurrence following breast 
conserving therapy is an important problem as it necessitates further surgery and endangers the 
overall survival of the patient. 
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Thus locoregional breast cancer recurrence is a heterogenous disease entity that encompasses 
small local recurrences occurring in the remaining breast tissue following primary breast 
conserving surgery as well as extensive chest wall recurrences following mastectomy occurring in 
the skin, subcutaneous tissue or musculoskeletal chest wall with or without regional nodal 
metastases.  
Ipsilateral breast tumour recurrence (IBTR)  
IBTR is defined as any subsequent, pathologically confirmed breast cancer in the ipsilateral breast 
that was originally treated with a lumpectomy (Clemons et al. 2001). The IBTR rate at 5 years 
varies between 2 – 15% (Kurtz et al. 1989; Veronesi et al. 1993; Fisher et al. 2002; Clarke et al. 
2005). Most IBTRs occur near to or at the site of prior resection (Veronesi et al. 1993; Fisher et al. 
2002; Siponen et al. 2011). Although clinical trials have shown BCT to be equivalent to mastectomy 
in terms of overall survival, IBTR remains a significant problem due to several reasons. Further 
surgery in the form of a mastectomy is recommended which results in quality of life and body 
image issues.  Local recurrences increase mortality and a 20% absolute reduction in 5 year local 
recurrence risk has been shown to lead to about a 5% absolute reduction in 15-year breast cancer 
mortality. In other words every fourth recurrence has been fatal (Clarke et al. 2005). Therefore 
treatment for IBTR should be effective firstly in terms of survival and secondly in terms of 
functional and aesthetic outcomes and morbidity. In addition any treatment for a local recurrence 
needs to be cost effective.The specific role of local (surgery and radiotherapy) and systemic 
(hormonal and chemotherapy) treatment in patients with IBTR remains unclear (Clemons et al. 
2003; Chen et al. 2008).  
Chest wall recurrence 
 
Approximately 5-10 % of patients undergoing mastectomy for operable breast cancer may suffer a 
chest wall or regional recurrence within 10 years (Harris et al. 1996; Hsi et al. 1998; Buchanan et al. 
2006; Elder et al. 2006; Siponen et al. 2013). Locally recurrent tumours occurring after an earlier 
mastectomy may involve only the superficial soft tissues and musculature of the chest wall but 
often invade the bony/cartilaginous chest wall. Chest wall recurrent breast cancer may be a sign of 
systemic disease and is considered to have a poor prognosis. The management of these patients is 
complex and different treatment combinations have been described but surgery is often not offered 
as primary therapy (Dahlstrøm et al. 1993; Willner et al. 1997; His et al. 1998; Rauschecker et al. 
2008).  
 
5.2.1 Risk factors for local recurrence  
The risk of locoregional recurrence depends on the initial stage of disease (Harris et al. 1996; Hsi et 
al. 1998; Buchanan et al. 2006; Elder et al. 2006) and most frequently cited risk factors include a 
positive resection margin, young age and presence of an extensive intraductal component (Huston 
and Simmons. 2005, Siponen et al. 2011). 
Radiotherapy after breast conserving surgery reduces the risk of locoregional breast recurrence by 
approximately 70% and improves survival compared to surgery alone in good prognosis breast 
cancer cases (Clarke et al. 2005; Siponen et al. 2011). 
Systemic adjuvant endocrine therapy significantly reduces the risk of local recurrences in oestrogen 
receptor (ER)-positive disease and similarly adjuvant chemotherapy reduces the local recurrence 
rate in women under 70 years of age (Early Breast Cancer Trialists' Collaborative Group. 2005). 
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Risk factors commonly associated with local recurrence after mastectomy include primary axillary 
lymph node metastasis, high grade tumour, large tumour size, young age at diagnosis and absence 
of steroid hormone receptors. A recent study from our institution showed hormone receptor 
negativity and HER2 gene amplification to be associated with local recurrence (Siponen et al. 
2013). 
 
5.2.2 Diagnosis and pre-treatment evaluation 
A local recurrence may manifest itself as a palpable or visible lesion/ lump near to the previous 
lumpectomy/mastectomy scar or may be detected on imaging during routine follow-up.  
Factors to consider in risk assessment and treatment decision making are listed below: (Cardoso et 
al. 2011) 
Disease-related factors: 
 Disease-free interval 
 Previous therapies and response 
 Biological factors (hormonal receptors, HER2) 
 Need for rapid disease/symptom control 
 
Patient-related factors: 
 Patient’s preferences 
 Biological age 
 Menopausal status 
 Co-morbidities and performance status 
 Socio-economic and psychological factors 
 Available therapies in the patient’s country 
 
Imaging  
Magnetic resonance imaging (MRI) has been recommended when other investigations have 
equivocal findings for its potential to differentiate malignancy from scarring.  However a recent 
systematic review by Quinn et al failed to support its use as a first-line investigation. They 
concluded that standard triple assessment (clinical assessment, mammography and core-needle 
biopsy) remained superior for diagnosis of recurrence (Quinn et al. 2012). 
Positron emission tomography-computed tomography (PET-CT) may also be useful for identifying 
the site of relapse, particularly when traditional imaging methods (plain x-rays, ultrasound, CT or 
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MRI) are equivocal or conflicting. It may also help identify or confirm the situation of an isolated 
locoregional relapse (Radan et al. 2006; Cardoso et al. 2011). 
Locoregional recurrence is frequently associated with distant spread, and such patients should 
undergo full staging procedures such as a bone scan and whole body CT before undergoing local 
treatments (Cardoso et al. 2011). 
 
5.2.3 Surgical treatment of locally recurrent breast cancer 
At present no standard guidelines exist for the management of a locally recurrent tumour. This is 
partly due to the heterogenous biological characteristics of local recurrences, coupled with a lack of 
good clinical trials that would provide evidence in support of a more specific management 
rationale. Despite this it is generally agreed that an isolated locoregional recurrence should be 
treated like a new primary tumour with a curative intent (Cardoso et al. 2011). 
5.2.3.1 Surgical treatment of ipsilateral breast tumour recurrence (IBTR)  
In a survey by Clemons et al, 97% of clinicians from all breast cancer specialties questioned, 
believed that an IBTR is curable and 99% recommended surgery (Clemons et al. 2003). Hence it is 
generally considered that patients with IBTR are candidates for a curative treatment approach 
including surgery with or without radiotherapy. Most would advocate a salvage completion 
mastectomy although a few studies have also demonstrated the possibility of repeat lumpectomy 
(Alpert et al. 2005; Ishitobi et al. 2011). Analysis of the SEER database by Chen and Martinez has 
however shown superior overall survival rates following salvage mastectomy (Chen and Martinez. 
2008). The 5-year survival rate after treatment for IBTR has been around 60-70% (Clemons et al. 
2001) and 5-year disease-free survival only about 30-50% (Haffty et al. 1996; van Tienhoven et al. 
1999). These figures have most likely been improving in recent years due to the introduction of new 
oncological treatment modalities.  
There are only a few reported series in the literature regarding treatment by SSM and immediate 
breast reconstruction (IBR) in the setting of a local recurrence. Usually these have been reported as 
part of larger series consisting of predominantly primary breast tumours treated by SSM and IBR 
(Carlson et al. 2003; Disa et al. 2003; Meretoja et al. 2007). 
Another unresolved issue concerns the management of the axilla in the setting of an IBTR 
especially when there is no clinical suspicion of tumour involvement of the axilla. If the primary 
BCT involved a node negative SLNB, should a completion axillary clearance be routine or is there a 
role for a further SLNB? (Koizumi et al. 2008; Derkx et al. 2010) The concern regarding repeat 
SLNB is that lymph drainage might be obscured by previous surgery and radiotherapy.  One recent 
study revealed that lymphatic mapping is possible after previous BCT with axillary treatment but is 
associated with a relatively low identification rate (41% after SLNB and 36% after ALND) 
(Maaskant-Braat et al. 2012). 
5.2.3.2 Surgical treatment of an isolated chest wall recurrence, chest wall 
stabilisation and reconstruction 
The precise role and timing of surgery remains unclear in chest wall recurrent breast cancer. 
Extensive recurrences in the skin of the chest wall are frequently regarded as stage 4 disease with a 
poor prognosis and has traditionally led to a reluctance to treat these cases with a radical surgical 
18 
 
approach. Surgery may also be considered too high-risk. Furthermore clinical decisions may be 
influenced by the local availability of plastic surgical and/or thoracic surgical expertise in cases 
where chest wall resection is required. Extensive chest wall resections should aim to achieve local 
control, improve survival and/or provide good palliation with low morbidity and mortality. Several 
series have demonstrated the safety of full-thickness chest wall resection (Arnold and Pairolero. 
1996; Cohen and Ramasastry. 1996; Faneyte et al. 1997; Toi et al. 1997; Chang et al.  2004; Losken 
et al. 2004; Pameijer et al. 2005) and favourable outcomes following chest wall resection for 
recurrent breast cancer have been reported with published 5 year survival rates ranging from of 
18% to 71% (Faneyte et al. 1997; Toi et al. 1997; Downey et al. 2000; Chagpar et al. 2003; Pameijer 
et al. 2005; Friedel et al. 2008; van der Pol et al. 2009; Noble et al. 2010). 
Surgery may also be performed as local therapy for disabling symptom palliation. Quality of life 
issues regarding alleviation of pain, haemorrhage, large malodorous ulcerations, recurrent 
infections and local control of the disease are important issues to consider. These potential benefits 
have been highlighted in a recent study (Veronesi et al. 2007). 
Effective local control of isolated chest wall recurrences is achieved with a wide excision whenever 
feasible. Soft tissue coverage can be performed with the use of direct closure, skin grafts, local skin 
advancement, the thoracoabdominal flap, the breast flap, the omentum flap, pedicled 
myocutaneous flaps, perforator flaps and free flaps. The choice of reconstruction depends on the 
location and size of the defect, availability of local and pedicled flap options, previous surgery or 
radiotherapy and the general condition and prognosis of the patient. Occasionally, small superficial 
recurrences can be excised leaving a superficial chest wall defect involving only the soft tissues. 
These can usually be treated with skin grafts and local flaps. More commonly however a more 
extensive soft tissue resection is required leaving bone or cartilage exposed. These cases warrant 
coverage with a flap of vascularised tissue (Tukiainen et al. 2003; Friedel et al. 2008; Aukema et al. 
2009). 
In cases of full-thickness defects of the bony chest wall with exposure of the vital structures, 
depending on anatomical location and defect size, some form of chest wall stabilisation may be 
required. Large anterior and antero-lateral thoracic wall defects usually require stabilisation to 
prevent flail chest and paradoxical breathing and to protect the underlying lungs and/or heart..A 
synthetic mesh is most commonly employed.  Using one or two rib grafts in combination with a 
mesh a large defect can be divided into smaller defects with adequate stability. Many centres use 
methylmethacrylate cement embedded between two layers of synthetic mesh which provides 
proper convexity and rigidity allowing slight movement (Arnold and Pairolero. 1996; Cohen and 
Ramasastry. 1996; Chang et al. 2004; Losken et al. 2004). Following chest wall stabilisation a 
vascularised flap reconstruction is then required to provide a water and air tight closure of the 
chest cavity, control infection, obliterate dead space, cover the synthetic material and close the soft-
tissue defect (Losken et al. 2004). Several options for flap reconstruction exist. The breast flap is a 
local flap that can be used to cover defects located mostly in the midline and is particularly useful 
in elderly patients who have other serious comorbidities. Regional flaps available include the 
latissimus dorsi musculocutaneous flap, pectoralis major muscle flap, serratus anterior muscle 
flap, vertical rectus abdominus myocutaneous (VRAM) flap, transverse rectus abdominis 
myocutaneous (TRAM) flap, thoracoabdominal flap, external oblique muscle flap and the greater 
omentum flap (Arnold and Pairolero. 1996). The latissimus dorsi muscle or musculocutaneous 
flaps are usually large, easy to elevate with a wide arc of rotation and can cover anterior, lateral and 
posterior regions of the chest as well as upper sternal defects. The use of the latissimus dorsi 
musculocutenous flap following mastectomy for breast cancer was first reported by Tansini in 1906 
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and after a long hiatus was ‘rediscovered’ and popularized by Neven Olivari (Olivari. 1976). The 
pectoralis major muscle flap can be based on the thoracoacromial or internal mammary vessels and 
is the workhorse flap for small to moderate defects over the upper or middle sternum and 
parasternal region. Pedicled VRAM or TRAM flaps can cover the epigastric and sternal areas as 
well as the anterolateral chest wall. The omentum flap is based on the right, left or both 
gastroepiploic vessels and can cover anterolateral chest wall defects. It is a soft and pliable flap and 
in wide defects requires a mesh to provide necessary stability. The omentum flap is usually covered 
with a skin graft. A shortcoming of this flap is the possible negative effect on respiration post-
operatively and risk of later ventral hernia.  The thoracodorsal artery perforator (TAP) flap is 
another pedicled option. It is a fasciocutaneous flap based on a musculocutaneous perforator or 
perforators from the thoracodorsal vessel axis and/or its vertical branch derivative. It provides a 
relatively thin and pliable skin paddle.   
Microvascular flaps may sometimes be necessary if local or regional flaps are unavailable or 
insufficient in size (Losken et al. 2004). The overall condition of the patient should be considered 
however as microvascular reconstruction is associated with longer operative times and the 
potential for anastomotic problems. The tensor fascia lata (TFL) myocutaneous, TRAM, deep 
inferior epigastric perforator (DIEP) and fillet forearm flaps are possible free flap options.  The TFL 
flap is easy and quick to harvest  both in the lateral or supine position and can provide a large flap 
area with a constant and reliable pedicle. The donor site has no influence on respiratory function. 
The TRAM flap is a reliable and large flap providing bulk which can be exploited in large 
intrathoracic defects as a filler or providing breast contour. The abdominal donor site may have an 
adverse affect on respiration post-operatively. Following forequarter amputation the resulting 
wound can usually be closed using the standard posterior flap but in some cases of more extensive 
tumour invasion necessitating chest wall resection a free flap reconstruction is indicated. In these 
cases the amputated extremity can provide a free flap if the forearm and distal upper arm are not 
affected by disease. This fillet of forearm free flap usually retains the ulna bone and after osteotomy 
and plate fixation can give stability and some contour to the shoulder.    
A recent study evaluated the functional outcome following chest wall reconstruction. They 
concluded that reconstruction provided adequate chest wall stability to maintain lung function but 
post-operative pain and sensation disorders were a frequent occurrence (Daigeler et al. 2009). 
If there is clinically no axillary lymph node involvement a repeat axillary dissection is probably 
unnecessary in patients who have previously undergone complete axillary clearance. 
 
5.2.4 Adjuvant therapy in locally recurrent breast cancer 
Evidence-based guidelines for treatment are lacking but most clinicians agree that treatment 
should be multimodal with a comprehensive multidisciplinary approach.The role of adjuvant 
therapy after surgery for IBTR is unclear, but one must consider patients with any indicators for 
poor prognosis as described earlier. It may therefore be appropriate to administer adjuvant therapy 
to those patients with clearly defined risk factors for disease relapse (Sirohi et al. 2009).  
5.2.4.1 Radiotherapy 
In patients who initially underwent breast conserving therapy for their primary tumour 
radiotherapy cannot be included in the multimodal treatment of the local relapse. However in 
patients not previously irradiated, full dose radiotherapy to the chest wall and (when indicated) 
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regional lymph node areas should be given. Sometimes re-irradiation to limited areas in the chest 
wall may be administered (Cardoso et al. 2011). In addition, the presence of healthy vascular flap 
tissue may enable the use of further radiotherapy. 
One study showed radiotherapy to significantly improve survival after surgery for chest wall 
recurrence (Chagpar et al. 2003). Radiotherapy has also been reported for its use as the primary 
treatment modality and in fact similar outcomes have been reported after surgery or radiotherapy 
for small isolated chest wall recurrences (Lê et al. 2002). 
5.2.4.2 Systemic therapy 
The effect of ‘secondary or pseudo-adjuvant’ systemic treatment is not well proven.  Existing data 
from the literature is difficult to interpret due to non-standardisation of therapies for local 
recurrences (Sirohi et al. 2009). 
The role of chemotherapy is subject to ongoing randomised trials (Wapnir et al. 2008) but these 
have been problematic due to slow accrual rates. Two earlier reports failed to show any clear 
benefit of chemotherapy, (Haylock et al. 2000; Rauschecker et al. 2001) the latter being a systemic 
review of randomised trials. 
However a survey revealed that 85% of clinicians advocated commencing systemic therapy if not 
previously given and 97% suggested a change in systemic therapy if the patient is already receiving 
some form of medical treatment (Clemons et al. 2003). In deciding whether or not to administer 
‘pseudo-adjuvant’ chemotherapy, factors such as tumour aggressiveness, previous adjuvant 
systemic therapy given, co-morbidities and preferences should all be considered (Cardoso et al. 
2011). 
‘Pseudo-adjuvant’ endocrine therapy despite being unproven, is commonly administered in cases 
of hormone receptor positive tumours because of its predicted benefit and low toxicity (Sirohi et al. 
2009; Cardoso et al. 2011). One study has shown hormonal therapy to be beneficial after 
locoregional recurrence but not chemotherapy (Halverson et al. 1992). 
Similarly ‘pseudo-adjuvant’ trastuzumab therapy is reasonable in cases where it was not prescribed 
at the time of initial diagnosis due to unavailability (Sirohi et al. 2009; Cardoso et al. 2011). 
 
5.2.5 Treatment of axillary recurrence 
Ipsilateral axillary nodal recurrence after previous axillary dissection is rare (0.7-1%) (Newman et 
al. 2000; Walsh et al. 2012; Siponen et al. 2012) but has been associated with a poor outcome 
(Walsh et al. 2012). Isolated ipsilateral axillary recurrence following an earlier negative SLNB is an 
even rarer event (0.2%) according to one recent report (Kapoor et al. 2012). In one series distant 
metastases developed in 50% of patients with an axillary recurrence and were more likely with 
uncontrolled axillary recurrences. Failure to receive multimodality therapy and failure to undergo 
surgery for the recurrence correlated with resistant axillary disease (Newman et al. 2000). 
Treatment should thus be surgical with an axillary dissection whenever possible. The role of post-
operative radiotherapy is unclear but is used in some institutions for patients who have not 
undergone prior axillary radiotherapy (Shikama et al. 2011).  
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5.2.6 Treatment of supraclavicular recurrence 
Ipsilateral supraclavicular lymph node recurrence is also very rare in breast cancer patients with 
reported rates of 1.3- 1.9% (Fan et al. 2010; Siponen et al. 2012). Prognosis is less favourable than 
that of patients with axillary recurrence. Surgery is usually not indicated as first-line therapy but 
instead radiotherapy and/or systemic therapy are favoured (Shikama et al. 2011). 
5.2.7 Prognosis of locally recurrent breast cancer 
Prognosis is influenced by a number of factors including: patient characteristics at primary 
treatment, extent of primary treatment and time interval from primary treatment to recurrence. 
Most IBTRs that occur at the site of prior resection are likely to be ‘true recurrences’ and are 
usually diagnosed earlier than recurrent cancers detected in other quadrants which can be 
considered as ‘new primary’ tumours. The latter have a better prognosis than true recurrences 
(Huang et al. 2002; Fredriksson et al. 2002; Nishimura et al. 2005). 
Indicators of poor prognosis after treatment for loco-regional failure include patients who were 
primarily node positive, hormone receptor negative, high nuclear grade (HER positive), short time 
interval from primary treatment to IBTR, evidence of lymphovascular invasion at time of IBTR, 
multiple nodules or recurrence in more than one site, young age and insufficient treatment of 
recurrence (Benson and Querci della Rovere. 2008). 
Many studies have shown that IBTR is associated with subsequent distant metastatic disease and 
worse survival. There is an ongoing debate as to whether IBTR is a cause of later distant metastases 
(Halstedian paradigm) or merely reflects tumour biology and is a manifestation of risk of distant 
relapse (Fisherian paradigm). In any case local recurrence within a conserved breast is the single 
most important predictor of overall survival (Benson and Querci della Rovere. 2008). 
With regards to chest wall recurrence a few studies have assessed the impact of prognostic factors 
on survival. Age >35 years, negative lymph node status at initial presentation, time interval to chest 
wall recurrence >2 years and use of radiotherapy for the recurrence have been shown to be 
statistically significant positive prognostic factors for better overall survival (Faneyte et al.  1997; 
Chagpar et al. 2003; Pameijer et al. 2005; Friedel et al. 2008; van der Pol et al. 2009). 
  
5.2.8 The Helsinki protocol for management of locally recurrent breast cancer 
 Salvage mastectomy for a local recurrence following breast conserving surgery. Immediate 
breast reconstruction possible in selected cases (Jahkola et al. 2003, Lindford et al. 2010, see 
also Figure 2). Repeat lumpectomy may be possible in rare selected cases (small easily 
discernible tumour in the scar). Post-operative radiotherapy if not earlier administered for the 
primary tumour (e.g. in the case of small DCIS). 
 Wide resection of a local recurrence following mastectomy with flap coverage when necessary. 
Post-operative radiotherapy if not earlier administered for the primary tumour.  
 Oncological medical therapy delivered according to same principles as for primary 
management and dependent on earlier administered therapy (Evidence-based medicine 
guidelines of diagnosis and treatment of breast cancer in Finland. 2007; NCCN guidelines®). 
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5.3 Breast reconstruction and locally recurrent breast cancer 
5.3.1 Timing of breast reconstruction 
Breast reconstruction is now a key part of comprehensive breast cancer treatment. Reconstruction 
may be performed in conjunction with the mastectomy (immediate reconstruction) or later 
(delayed reconstruction) after a suitable length of follow-up time (1-2 years).The timing of delayed 
reconstruction depends on oncological considerations such as mastectomy indication, tumour type 
and lymph node status and adjuvant therapy. In practice delayed reconstruction is considered at 
least half a year after the completion of primary oncological therapy and/or once irradiated tissue 
has had time to recover. Originally most reconstructions were delayed but owing to a gradual 
paradigm shift in breast cancer treatment the concept of immediate reconstruction has become 
more accepted (Losken and Jurkiewicz. 2002; Rainsbury. 2006). SSM followed by immediate 
breast reconstruction (IBR) was first described in 1991 and involves the removal of all the breast 
tissue, the nipple–areolar complex (NAC) and any biopsy scar (Toth and Lappert. 1991). The 
dissection plane of SSM progresses between the breast parenchyma and the subcutaneous fat 
(Figure 1). SSM enables a superior aesthetic result in comparison to either simple mastectomy and 
IBR or delayed reconstruction. An earlier retrospective study (Al-Ghazal et al. 2000) and a recent 
prospective study (Elder et al. 2005) have both demonstrated the positive effects of immediate 
breast reconstruction on the psychological well-being of patients with breast cancer. Other 
advantages of SSM and IBR include the retention of breast skin sensation and cost effectiveness as 
only one operation is required. The nipple-sparing mastectomy (NSM) has recently gained in 
popularity with the aim of further improving the aesthetic result. The incidence of cancer in the 
retained nipple after risk-reducing mastectomy has been reported to be less than 1 per cent. A 
recent review concluded that NSM appears to be an acceptable technique for women undergoing 
risk-reducing mastectomy and in the therapeutic setting may be offered to patients with smaller 
tumours far from the nipple and favourable pathological features. Women should however be 
counselled about possible nipple necrosis and the potential for local recurrence (Rusby et al. 2010). 
Photo: Juhani Lassander 
Figure 1. Skin-sparing mastectomy 
5.3.2 Choice of reconstruction 
The type of reconstruction is individualised and must consider medical comorbidities, body 
habitus, the oncological treatment plan and patient preference. The reconstruction may be based 
on implants, autologous tissue or a combination of the two. The donor sites favoured for 
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autologous reconstruction include the abdomen [the free transverse rectus abdominis 
myocutaneous (TRAM), deep inferior epigastric artery perforator (DIEP) and superficial inferior 
epigastric artery (SIEA) flaps], the latissimus dorsi (pedicled musculocutaneous latissimus dorsi 
flap with or without implant) pedicled thoracodorsal artery perforator (TAP) flap or pedicled 
intercostal artery perforator (ICAP) flap, the gluteal region [free superior gluteal artery perforator 
(SGAP) and inferior gluteal artery perforator (IGAP) flaps] and the thigh region [free transverse 
myocutaneous gracilis (TMG) flap]. In Helsinki the abdomen and back are the favoured donor 
sites. 
5.3.3 Breast Reconstruction as a risk factor for local recurrence 
Immediate breast reconstruction (IBR) for the treatment of early stage breast cancer has increased 
in popularity over the past two decades. The oncological safety of IBR has been addressed in 
several studies (Meretoja et al. 2007; Vaughan et al. 2007; McCarthy et al. 2008; Yi et al. 2011; 
Patterson et al. 2012) but only a few have considered the oncological safety of delayed autologous 
breast reconstruction (Nieminen et al. 1999). Moreover, in most studies a control group with 
mastectomy only has been lacking.  
A few studies directly comparing patients treated with mastectomy only and patients receiving a 
reconstruction have been recently reported. Isern et al reported a higher incidence of recurrent 
disease in women treated with delayed autologous tissue (pedicled and microvascular flaps) 
reconstructions when compared to a matched group of women treated with mastectomy alone 
(Isern et al. 2011). In contrast to the aforementioned Swedish study (Isern et al. 2011) other studies 
have reported no significant difference in the locoregional recurrence (LRR) rate (McCarthy et al. 
2008; Reddy et al. 2011; Eriksen et al. 2011; Agarwal et al. 2012). However, two of the previous 
studies have comprised of only implant reconstructions (McCarthy et al. 2008; Eriksen et al. 2011) 
while a recent comparative study by Nedumpara et al included both LD myocutaneous flaps (60%) 
and implants only (40%)(Nedumpara et al. 2011). Furthermore a recent meta-analysis 
demonstrated no evidence for increased LR with IBR compared with mastectomy alone (Gieni et 
al. 2012). 
There have been a few studies that discuss the somewhat contentious possibility of surgery-driven 
enhancement of metastasis (Tagliabue et al. 2003; Demicheli et al. 2008). In fact the capacity of 
tumour surgical resection to enhance cancer growth at metastatic sites was a theory postulated 
already a century ago. Could the additional surgery of a major autologous reconstruction pose a 
risk in some patients? Low LR and LLR rates have however been earlier reported following free 
TRAM flap reconstructions (Nieminen et al. 1999; Patterson et al. 2012). The latter study reported 
a LRR rate of 4.6% with a median follow-up of 69.2 months. 
5.3.4 Oncological aspects of skin-sparing mastectomy (SSM) 
There had been previously debate over how often the skin itself is involved in patients with breast 
cancer. Two classic studies by Fisher and Wertheim found rates of non-NAC skin involvement of 
4.4% and 11.3%, respectively (Fisher et al. 1975; Wertheim and Ozzello.1980). Thus there is a 
general consensus that patients with clinically involved skin, including inflammatory breast cancer 
cases are not candidates for SSM (Rainsbury. 2006). Care should also be taken when offering this 
procedure to women with large tumours. 
The SSM skin-flap should be dissected as thin as possible in order to remove all glandular breast 
tissue and avoid residual disease. However, the blood supply to the skin flaps should not be 
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compromised and the perforating arteries should be preserved whenever possible (Jahkola et al. 
2004). A study by Torresan RZ et al revealed residual breast tissue in the skin after SSM in 9.5% of 
cases and was associated with skin flaps greater than 5 mm thick (Torresan et al. 2005). In a recent 
study residual breast tissue was reported to occur in 6% of SSM cases but with no adverse effect on 
oncological outcome. However their follow-up time was only 33.5 months (Dreadin et al. 2012).  
Another issue that has been debated is the oncological significance of the inframammary fold 
(IMF). The IMF is a zone of adherence of the superficial fascial system to the underlying chest wall 
and anatomically denotes where the skin of the inferior pole of the breast parenchyma meets the 
chest wall forming a groove known as the inframammary crease. Preservation of the IMF during 
mastectomy facilitates breast reconstruction but there have been concerns regarding the amount of 
breast tissue that might potentially be left unresected. One study showed that 28% of IMF 
specimens contained breast tissue and intramammary lymph nodes (Gui et al. 2004) and so 
concluded that caution should be exercised in minimising the possibility of residual breast tissue. 
5.3.5 Diagnosis of local recurrence post-breast reconstruction 
As for local recurrences in the non-reconstructed breast early detection is essential for successful 
management with salvage surgery with good margins and subsequent adjuvant therapies 
(Langstein et al. 2003; Howard et al. 2006). There is no consensus as to how follow-up after IBR 
should be conducted. Regular clinical examinations are the basis for all follow-up protocols but 
much variation exists in their frequency as well as the use of mammography and ultrasound. Helvie 
et al found that the appearance of recurrent tumour in TRAM flaps on mammography is similar to 
that of primary breast cancer (Helvie et al. 1998). Some have advocated the use of computed 
tomography and MRI for follow-up imaging of reconstructed breasts (Lindfors et al. 1985; LePage 
et al. 1999; Peng et al. 2011). MRI may be superior for visualization of the normal TRAM flap 
appearance and for differentiating benign from malignant changes (Devon et al. 2004). In one 
study all LRRs after TRAM flap reconstruction were identified clinically without the use of imaging 
(Patterson et al. 2012). In fact most recurrences tend to occur superficially in the skin or 
subcutaneous tissues and often present as a palpable mass or thickening (Newman et al. 1998; 
Shaikh et al. 2001; Patterson et al. 2012; Lee et al. 2012). Shaikh et al concluded that clinical 
examination and biopsy is the most reliable method of detection and that other imaging techniques 
should not be routine (Shaikh et al. 2001). However there have been concerns that a deeply lying 
chest wall recurrence might be concealed by a TRAM flap leading to a delay in diagnosis. Even 
though one study disproved this notion (Langstein et al. 2003) there may well be a reasonable 
argument for imaging as a screening tool at regular intervals. But this is unlikely to be cost-effective 
as the majority of post reconstruction recurrences are superficial. In Helsinki routine follow-up 
after IBR consists of mammography and ultrasound as well as clinical examination by a surgeon 
and/or oncologist at 1,3 and 5 years from surgery (Meretoja et al. 2007). 
5.3.6 Treatment of local recurrence post-breast reconstruction 
The treatment of locally recurrent breast cancer following reconstruction is not clearly defined but 
should be multimodal. As for locally recurrent disease in the non-reconstructed breast restaging 
with CT or PET-CT seems appropriate (Radan et al. 2006; Cardoso et al. 2011). Most institutions 
carry out a wide surgical resection with removal of as much reconstructed tissue as necessary to 
achieve negative margins (Chagpar et al. 2004; Howard et al. 2006). Complete flap removal may be 
necessary. A chest wall recurrence may also be amenable to surgical resection with use of the 
remaining TRAM flap for subsequent defect closure (Langstein et al. 2003; Howard et al. 2006). 
However these cases tend to be more complex and chest wall reconstruction and coverage with a 
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new autologous flap may be indicated. One series reported similar oncological outcomes when 
comparing chest wall recurrence after reconstruction to recurrence after mastectomy with no 
breast reconstruction (Chagpar et al. 2004). Adjuvant therapy should be instituted according to 
previously outlined principles for recurrent disease (Langstein et al. 2003; Howard et al. 2006). 
Radiotherapy administered to the remaining flap may however incur compromised flap aesthetics 
from fibrosis and scar contracture as well as fat necrosis and volume loss (Howard et al. 2006). 
 
5.4 Secondary cancer after earlier primary breast cancer 
Women treated for a primary breast cancer have a 25% increased risk of developing a second new 
primary non-breast cancer. These include many different cancer types (stomach, colorectal, lung, 
soft tissue sarcoma, melanoma, non-melanoma skin, endometrium, ovary, kidney, thyroid gland 
and leukaemia) that have been reported and may result from shared risk factors such as genetics, 
environmental factors and breast cancer treatments. In fact a 6-fold increased risk of thorax and 
upper limb sarcomas has been reported, which suggests that these cancers may be related to 
radiotherapy (RT) (Mellemkjaer et al. 2006). 
5.4.1 Radiation induced sarcoma 
Ionizing radiation is known to be a potent carcinogen and malignancy associated with radiation 
may result from natural sources, a radiation accident or may be a side effect from cancer therapy. 
The classical definition of radiation induced sarcoma is based on criteria proposed in 1948 by 
Cahan et al:  
1. History of RT.  
2. Asymptomatic latency period of several years.  
3. Occurrence of sarcoma within a previously irradiated field.  
4. Histological confirmation of sarcoma that is histologically unique from the primary cancer.  
The most common histological types of radiation induced sarcoma previously reported by the 
Finnish Cancer Registry were osteosarcoma and malignant fibrous histiocytoma and these were 
mostly high grade tumours (Wiklund et al. 1991). The actual pathophysiological mechanism of 
radiation induced sarcoma has not yet been elucidated. 
5.4.2 Angiosarcoma 
Angiosarcomas (AS) are rare aggressive malignant tumours that usually arise from the endothelial 
cell lining of vascular or lymphatic channels and have a poor prognosis. They account for only 1% of 
all soft tissue sarcomas and can arise in any soft-tissue structure or viscera. They most commonly 
occur in the skin of the scalp and/or face in elderly patients and do not appear to have any clear 
predisposing factors (Young et al. 2010). Approximately 8% of angiosarcomas arise in the breast. 
Primary breast AS which is not associated with radiotherapy typically presents as an ill-defined 
mass in the breast parenchyma in younger women and consists of 1 in 1700-2000 primary breast 
cancers (Enzinger FM, Weiss SW. 1995). 
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5.4.2.1 Radiation-associated breast angiosarcoma 
Secondary breast AS usually occurs in older women with a history of breast cancer and RT, and is 
mostly cutaneous presenting with multiple closely-related lesions (Monroe et al. 2003; Lucas. 
2009). Six cases of secondary angiosarcomas were first reported as arising in the long-standing 
oedematous upper extremity following mastectomy and axillary clearance and designated the 
Stewart-Treves syndrome (Stewart and Treves. 1948). Stewart and Treves recognized that an 
oedematous arm after radical mastectomy for breast cancer may suggest recurrent breast cancer, 
but that long-standing chronic oedema without recurrent cancer may occasionally produce "a 
heretofore unrecognized and unreported sequel ... long after the malignant breast neoplasm has 
apparently been arrested ... a new specific tumor." Stewart and Treves suggested that these 
angiosarcomas were probably not observed previously because they were mistaken for recurrent, 
inoperable, cutaneous manifestations of breast cancer. Lymphoedema caused by Milroy’s disease 
and chronic infections, like filariasis, have similarly been associated with the development of 
angiosarcomas. But over the last 10-20 years cutaneous AS in the irradiated breast after breast 
conserving therapy (BCT) has been increasingly reported (Fineberg and Rosen. 1994; Karlsson et 
al. 1998; Strobbe et al. 1998; Cozen et al. 1999; Marchal et al. 1999; Huang and Mackillop. 2001; 
Yap et al. 2002; de Bree et al. 2002; Feigenberg et al. 2002; Monroe et al. 2003; Billings et al. 
2004; Cha et al. 2004; Brenn and Fletcher. 2005; Kirova et al. 2005; West et al. 2005; Vorburger 
et al. 2005; Hodgson et al. 2007; Lucas. 2009; Mery et al. 2009; Biswas et al. 2009; Hui et al. 
2012; Morgan et al. 2012; Seinen et al. 2012; Jallali et al. 2012). The association between RT and 
AS has been established by a number of studies (Cozen et al. 1999; Huang and Mackillop. 2001; 
Yap et al. 2002; Mery et al. 2009).  
RT induced AS occurring in the breast skin/parenchyma or chest wall following BCT or 
mastectomy is probably the most common form of RT induced AS. Post RT angiosarcomas have 
also been described as intraabdominal or abdominal wall masses following RT for cervical, ovarian 
or uterine carcinoma.  
Huang and Mackillop demonstrated that the relative risk of AS doubled after breast cancer surgery 
even if no RT had been administered (Huang and Mackillop. 2001). This suggests a possible 
multifactorial aetiology and the increased risk might result from coexisting lymphoedema. 
Additionally some reports suggest that mutations in the DNA repair genes, BRCA1 and BRCA2, 
predispose to angiosarcomas after treatment for breast cancer (West et al. 2012). One recent cohort 
study even failed to show such a strong association between RT and breast AS (Virtanen et al. 
2007). 
Although AS following BCT is rare with a reported prevalence of 0.05% (Marchal et al. 1999), it is 
associated with high rates of recurrence and poor overall survival of about 35% at 5 years (Marchal 
et al. 1999; Monroe et al. 2003; Billings et al. 2004; Cha et al. 2004; Hodgson et al. 2007)(Figure 
2). 
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Figure 2. AS is an aggressive tumour with high rates of local recurrence. 
 
5.4.2.1.1 Clinical features 
Radiation-associated AS clinically presents as an erythematous patch, plaque or nodule, often with 
local oedema. It may initially resemble a bruise. Other early findings include ulcerations, eczema 
and nonpigmented macules. Pain is uncommon. Differential diagnoses include trauma, infectious 
pathology, haemangioma-like lesion, or inflammatory carcinoma. Involvement of the breast is 
frequently extensive and the lesions are commonly multiple (Monroe et al. 2003; Brenn and 
Fletcher. 2005; West et al. 2005; Lucas. 2009). 
 
5.4.2.1.2 Histopathology 
Histologically AS may be high grade and exhibit varying degrees of nuclear atypia, darkly staining 
nuclei, large nucleoli and frequent mitoses. Intraluminal ‘blood lakes’ are a common feature. 
However histological features can vary between cases and distinguishing between a malignant 
vascular tumour and a benign lesion can be difficult. Immunohistochemical tests can help 
diagnostically with factor VIII antigen, CD34 and CD31 markers mostly used (Monroe et al. 2003; 
Brenn and Fletcher. 2005; Lucas. 2009). 
 
5.4.2.1.3 Diagnosis 
Early diagnosis of AS is of paramount importance due to its aggressive progression. However as it 
can be mistaken for a simple benign lesion presentation and diagnosis may be delayed. Thorough 
physical examination and prompt multiple punch biopsies are essential to confirm histology. Other 
investigations such as mammography and MRI play only a limited role in diagnosing AS, (Monroe 
et al. 2003; West et al. 2005; Hodgson et al. 2007) although MRI is probably superior. 
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5.4.2.1.4 Management 
Surgical treatment 
Most reports of AS treatment are limited to retrospective case series and no evidence-based 
guidelines exist. However treatment of choice is radical surgery with complete (R0) resection in 
view of its high probability of recurrence. Surgery usually consists of a simple/radical mastectomy 
or wide local excision (Strobbe et al. 1998; Marchal et al. 1999; Feigenberg et al. 2002; Monroe et 
al. 2003; Billings et al. 2004;Cha et al. 2004; Vorburger et al. 2005; West et al. 2005; Hodgson et 
al. 2007;Biswas et al. 2009; Young et al. 2010; Hui et al. 2012; Morgan et al. 2012; Seinen et al. 
2012; Jallali et al. 2012). Involved margins (R1 and R2 resection) are common because of the 
invasive and frequently multifocal nature. One study advocated resection of all at-risk irradiated 
breast skin to reduce local recurrence (Morgan et al. 2012). Following extensive resection options 
for defect reconstruction include:  split-thickness skin grafting, pedicled latissimus dorsi 
musculocutaneous flap, pedicled vertical rectus abdominis (VRAM) flap, pedicled omental flap or 
free tissue transfer (Hui et al. 2012; Seinen et al. 2012; Jallali et al. 2012). Skin grafting in an 
earlier irradiated field may not be the most appropriate option and flap coverage may be 
preferable. At present there are no standard guidelines concerning surgical margins and choice of 
reconstruction. Single institution series have reported median overall survival up to 4 years with 
distant metastasis rates up to 41% (Billings et al. 2004, Vorburger et al. 2005; Morgan et al. 2012; 
Seinen et al. 2012). 
Regional lymph node involvement is uncommon either at presentation or at recurrence; hence 
routine axillary lymph node dissection is not indicated (Monroe et al. 2003). 
Adjuvant therapy 
The use of other adjuvant treatment modalities in the management of AS has yet to be clearly 
defined. Adjuvant radiotherapy is generally avoided in radiation-associated angiosarcomas as the 
surrounding tissue has usually already received the maximum dose of radiotherapy (Young et al. 
2010). 
In one series 67% patients received adjuvant chemotherapy with variable therapeutic regimens 
(Vorburger et al. 2005). In a phase II trial, promising results with the taxane paclitaxel have been 
reported (Penel et al. 2008).  
C-kit proto-oncogene product (KIT, CD117) is a tyrosine kinase growth factor receptor for stem cell 
factor. This receptor is important for the development and maintenance of hematopoietic stem 
cells, mast cells, germ cells, melanocytes, and interstitial cells of Cajal and is constitutively 
expressed in them. The expression of KIT receptor tyrosine kinase in post-radiation angiosarcoma 
has been reported and may provide a potential treatment target (Komdeur et al. 2003). 
In view of the fact that angiosarcomas are endothelial-cell tumours, there is currently much 
interest in the role of angiogenesis and angiogenic factors associated with their pathogenesis and 
how they might be used as therapeutic targets (Young et al. 2010). The potential of antiangiogenic 
molecules such as the VEGF-A monoclonal antibody, bevacizumab, has been recently reported 
(Agulnik et al. 2012). 
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6. AIMS OF THE STUDY 
 
The aim of the present study was to investigate and report the surgical and oncological results of 
reconstructive surgery in relation to locally recurrent breast malignancy. 
The specific aims were: 
I  To investigate whether skin-sparing mastectomy (SSM) and immediate breast 
reconstruction (IBR) is a suitable treatment option in selected cases of locally 
recurrent breast cancer after previous breast conserving therapy (BCT). 
II To assess local control, morbidity, choice of flap reconstruction, patient selection and 
overall long-term survival following surgical salvage of patients with chest wall 
recurrent breast cancer. 
III To evaluate the oncological impact of breast reconstruction in breast cancer patients 
treated with mastectomy. 
IV To investigate the surgical management of radiation-associated cutaneous breast 
angiosarcoma with an emphasis on outcome, surgical margins and choice of 
reconstruction. 
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7. PATIENTS AND METHODS 
7.1 Patients (Studies I-IV) 
The study was carried out at the Helsinki University Hospital. All of the patients were operated on 
in the Department of Plastic Surgery and in the Breast Surgery Unit. Study I consisted of 60 
consecutively operated patients who were treated by SSM and IBR between 1995 and 2008 for an 
ipsilateral breast tumour recurrence (IBTR). Study II consisted of 40 consecutively operated 
patients who were treated with wide soft tissue resection and immediate flap reconstruction for an 
extensive chest wall recurrent breast cancer between 1984 and 2011. Study III was based on 522 
consecutive patients who underwent mastectomy with or without breast reconstruction between 
January 2000 and December 2003. Study IV consisted of 10 patients diagnosed between 1999 and 
2010 with a cutaneous breast angiosarcoma after earlier treatment with radiotherapy for primary 
breast cancer.The study protocol was approved by the Ethics Committee and Head of Surgery of 
the Helsinki University Central Hospital and permission was granted for examination of patient 
records. 
 
Study I 
The patient population consisted of 60 consecutive patients managed by SSM and IBR between 
1995 and 2008 for an ipsilateral breast tumour recurrence (IBTR).  All these patients had their 
primary breast cancer earlier treated by breast conserving surgery and radiotherapy. Patients 
selected for treatment were those who had been diagnosed with a locally recurrent tumour 
considered to have a favourable prognosis. Our written selection criteria (Jahkola et al. 2003) are 
shown in Figure 2. 
Hospital records were analysed for demographic, oncological and reconstructive data. Pathology 
reports were also reviewed to obtain tumour characteristics and surgical records were analysed for 
follow-up data on patterns and timing of re-recurrence and patient outcome.  In addition the 
selection criteria were analysed for each case. 
 
Figure 2. Selection criteria for SSM and IBR (Jahkola et al. 2003). 
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Study II 
40 patients were identified from our surgical database that had been treated with wide soft tissue 
resection and immediate flap reconstruction with or without a complete full-thickness chest wall 
resection for an extensive chest wall recurrent breast cancer between 1984 and 2011.Their medical 
records were retrospectively reviewed for primary breast cancer and recurrent disease data 
including analysis of surgical and histological records. Oncological outcome was assessed with 
respect to overall survival (OS) and disease-free survival (DFS).  
 
Study III 
The study was based on 522 consecutive patients, younger than 70 years, who underwent 
mastectomy between January 2000 and December 2003 for invasive breast cancer. Overall, 391 
(75%) received mastectomy alone and 131 (25%) underwent a breast reconstruction of which 13 
(10%) were immediate and 118 (90%) were delayed reconstructions. Data on cancer recurrence and 
survival were collected from hospital records and registries, and the files of the Finnish Cancer 
Registry. Recurrences were classified as local, regional and systemic according to the first site of 
recurrence. Local recurrence (LR) is defined as any recurrence of tumour in the ipsilateral thoracic 
wall and LRR as any recurrence in the ipsilateral thoracic wall or regional lymph nodes or in both. 
Study IV 
10 patients were diagnosed between 1999 and 2010 with a cutaneous breast angiosarcoma after 
earlier treatment with radiotherapy (RT) for breast cancer. All primary breast tumours were ductal 
carcinomas staged I-III. RT was delivered in a standard fashion consisting of a tangential external 
beam field technique with the patient in a supine position. 25 fractions of 2 Grays (Gy) were 
administered over 5 weeks resulting in a total dose of 50 Gy. All patients received the same regimen 
and total dose. 1 patient received a further dose of 15/3 Gy to the tumour bed 2 weeks later. 1 
patient later underwent skin-sparing mastectomy and immediate reconstruction with a free 
transverse rectus abdominis myocutaneous (TRAM) flap for an ipsilateral breast tumour 
recurrence prior to the development of AS. 
Clinical features of AS were evaluated using photographs taken at presentation. Surgical operation 
notes were analysed and pathology reports reviewed to obtain AS tumour characteristics and 
macroscopic and microscopic resection margins. Follow-up data on recurrence and overall survival 
was obtained from surgical and oncological records.  
All cases were reviewed pre-operatively by the multidisciplinary Helsinki Sarcoma group. This 
group discusses routinely a management plan for all soft tissue sarcomas and decisions are made 
regarding:  
1. Neoadjuvant therapy 
2. Surgery/ macroscopic margins  
3. Adjuvant medical therapy 
4. Radiotherapy 
 
32 
 
7.2 Surgery (Studies I-III) 
Study I   
SSM was performed in an established manner by experienced breast surgeons. The nipple-areola 
complex was removed along with the entire remaining breast parenchyma and previous resection 
or biopsy scars. In the case of a more superficially recurrent tumour an extended area of skin was 
also included in the excision. SSM was combined with axillary lymph node dissection in those cases 
when the axilla had not earlier been treated. In a few cases SLNB was carried out. The SSM was 
followed by IBR carried out by a team of reconstructive surgeons.  
Study II 
 
The resection was considered potentially curative if preoperative staging investigations showed 
that the resection could be radical. Resection with a palliative intent was carried out in patients 
who presented with distant metastases and/or an extensive tumour with overwhelming local 
symptoms in which a radical excision was not considered possible.  
The resection and soft tissue / chest wall reconstruction were performed by a team of plastic 
surgeons. Excision margins were pre-operatively planned in conjunction with a senior radiologist 
based on CT scan findings.  For recurrences limited to the soft tissues of the chest wall the resection 
was performed down to the bony chest wall including the pectoralis major and minor muscles and 
the fascia of the serratus anterior and rectus abdominus muscles. The minimum lateral 
macroscopic margin was 2 to 3 cm. An axillary clearance was carried out if not previously 
performed or if there was evidence of axillary recurrence. In the full-thickness chest wall resection 
cases a complete en bloc resection of skin, muscle and full-thickness bony chest wall was 
performed. The deep margin usually included the parietal pleura. An extended forequarter 
amputation was indicated when the tumour recurrence was located in the shoulder and axillary 
region with involvement of the chest wall, axillary vessels and brachial plexus. In these cases 
resection of ribs as well as removal of the upper limb, scapula and clavicle was performed. 
Definitive chest wall stabilisation was then carried out followed by immediate soft tissue 
reconstruction with a pedicled or microvascular flap. If the bony chest wall defect measured up to 5 
x 5 cm only a mesh was used, up to 10 x 10 cm a free rib graft and mesh were used and if the defect 
measured up to 10 x 25 cm two free rib grafts and a mesh were applied. The early cases were 
treated with fascia lata for chest wall stabilisation.  
 
Figure 3. Wide en bloc resection of chest wall recurrence with 3 cm lateral margins. FTCWR of 
lower sternum and left lower 3 ribs and parietal pleura. Chest wall stabilisation with prolene mesh 
and defect covered with pedicled musculocutaneous latissimus dorsi flap.  
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Study  III 
 
The median age at primary diagnosis was 53 years (range 24-69 years). The median follow-up time 
was 8.5 years (range, 9-130 months) calculated from the date of primary surgery. A skin-sparing or 
non-skin-sparing mastectomy was performed by experienced breast surgeons. In conjunction with 
the mastectomy all patients underwent either sentinel lymph node biopsy (SLNB) (n=68), axillary 
lymph node dissection (ALND) (n=348) or both (n=106). All SLNB patients underwent back-up 
ALND regardless of the sentinel node status from January 2000 to May 2000. From June 2000, 
ALND was omitted in sentinel node negative patients with radiologically unifocal breast cancer up 
to a maximum tumour diameter of 3 cm when evaluated with breast ultrasound. The mastectomy 
specimens as well as sentinel node and ALND specimens were assessed as described in detail in a 
previous study (Siponen et al. 2011). 
An immediate or delayed breast reconstruction was carried out by a team of reconstructive plastic 
surgeons. The main indication for immediate reconstruction was extensive DCIS as a preoperative 
diagnosis. Delayed reconstruction was offered to patients with node negative invasive breast cancer 
within 1 year after primary surgery and for patients with node positive disease 2-4 years from 
primary surgery. The median time from mastectomy to delayed breast reconstruction was 34 
months. Median follow-up after delayed breast reconstruction was 64 months (range 5-111 
months). The reconstruction method was determined by patient anatomy and preferences and a 
variety of methods were used. (Table 1) 
Table 1. Type of breast reconstruction (Study III) 
Type of breast reconstruction 
(n=131) 
Immediate 
reconstruction 
 (n=13) 
Delayed 
reconstruction 
(n=118) 
Pedicled flap (n=72) 
LD musculocutaneous  flap +/- implant 
TRAM flap 
Thoracodorsal artery perforator (TAP) flap + 
implant 
TAP and intercostal artery perforator (ICAP) flaps 
 
7 
 
31 
10 
1 
1 
Microvascular flap (n=53) 
TRAM flap 
DIEP flap 
SIEA flap 
 
6 
 
32 
14 
1 
Implant only (n=6)  6 
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7.3 Adjuvant therapy (Studies I-IV) 
Studies I and II 
Following surgical treatment of the locally recurrent tumour ‘secondary or pseudo’ adjuvant 
therapy was administered according to individual patient risk factors for disease relapse.   
Study III 
Following mastectomy, radiotherapy (RT) was given according to hospital guidelines for tumour 
stage pT3and/or pN2. RT to regional nodes was recommended for all N2-N3 patients and during 
2000-2001 also to N1 patients. During 2002-2003 nodal RT was recommended for patients with 
more than one macrometastatic axillary lymph node.  
Systemic adjuvant treatment was administered based on the patient and disease characteristics at 
the discretion of the treating physician.  In general, women with node-positive disease and those 
considered to have moderate-to-high risk node-negative disease received adjuvant systemic 
therapy.  Premenopausal women with oestrogen receptor (ER)- or progesterone receptor (PgR)-
positive cancer received tamoxifen and postmenopausal women either tamoxifen or an aromatase 
inhibitor for 5 years. Patients <65 years of age with moderate-to-high risk HER2-positive cancer 
received adjuvant trastuzumab and chemotherapy.  
Study IV 
With a lack of a general consensus concerning the benefit of adjuvant therapy in AS it has not been 
standard practice to administer adjuvant therapy in our institution. However in one case the 
administration of chemotherapy (paclitaxel) was prompted by the appearance of a local recurrence 
one month following radical surgery.   
 
7.4 Follow-up (Studies I-IV) 
Studies I and III 
Patients were followed-up according to a standard protocol at the same institution, initially at 4-6 
weeks after surgery. Thereafter clinical examination, blood cell counts and blood chemistry and 
bilateral mammography with or without breast ultrasonography at 1-2 yearly intervals was adhered 
to in all patients. When a recurrence was suspected, an isotope bone scan and computed 
tomography were usually carried out as the initial staging examinations.  After the first 5 years, 
follow-up was continued at a local health-care centre or at a private health-care company according 
to patient preference. 
Study II 
Following surgery for chest wall recurrent breast cancer follow-up was initially at 4-6 weeks after 
surgery and then yearly clinical checks with chest x-ray and when indicated CT chest/ MRI 
examination for 5 years. In some cases (n=8) yearly follow-up occurred in the patient’s own district 
hospital. 
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Study IV 
All cases were reviewed 1 month post operation by the multidisciplinary Helsinki Sarcoma group. 
All patients were then followed-up by a standard protocol at the same institution, initially at 4-6 
weeks after surgery. Thereafter a protocol of clinical examination at 3 monthly intervals with chest 
x-ray and 6 monthly CT chest/MRI examination for 2 years was adhered to in all patients. This was 
followed by yearly clinical examination and CT chest/MRI examination for a further 5 years.  
 
7.5 Statistical methods (Studies I-IV)  
Study I 
The Chi-squared test was used to compare disease relapse rates in the two groups of patients who 
did and did not meet the selection criteria. 
 
Study II   
 
Kaplan-Meier curves were used to analyse survival. Statistical significance was set at a P value of 
<0.05. Log-rank analysis was used for univariate analysis of possible prognostic factors. Cox 
regression analysis was used for factors found significant on univariate analysis. (SPSS® for 
Windows® version 17.0; SPSS, Chicago, Illinois, USA). 
 
Study III 
Primary tumour characteristics were compared between the reconstruction and no reconstruction 
groups using the Chi-squared test. The 8-year estimate for LRR was computed using the Kaplan-
Meier method. Breast cancer specific survival (BCSS) was calculated from the date of surgery to the 
date of death considered to be caused by breast cancer, and overall survival (OS) from the date of 
surgery to the date of death from any cause. Life tables were constructed according to Kaplan-
Meier method and LRR free survival, distant metastases (DM) free survival, BCSS and OS between 
the groups was compared with the log-rank test and Cox proportional hazards models. P values of 
<0.05 were considered as statistically significant. (SPSS® for windows®version 20.0; SPSS, 
Chicago, Illinois, USA). 
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8. RESULTS 
8.1  Study I 
59 patients had stage 0-2 disease at primary operation (10 patients stage 0, 36 patients stage 1, 13 
patients stage 2) and 1 patient stage 3 disease. 
The local recurrence was initially detected by the patient in one third of cases and the remainder 
during follow-up by clinical and radiographic examination. The median length of time from 
primary therapy to local recurrence was 48 months (range 12-240 months). In 6 cases (10%) there 
was a clear difference in the histological type of tumour when comparing the primary tumour to the 
IBTR. 
The reconstruction method was determined by patient anatomy and preferences, and a variety of 
methods was used as judged appropriate. Forty free flaps were performed. (Table 2) The mean age 
at surgery was 53 years. Axillary management consisted of axillary clearance (62%), no treatment 
(31%), SLNB (5%), and SLNB followed by axillary clearance (2%).   
Table 2 Type of breast reconstruction (Study I) 
Type of breast reconstruction n=60 
Free TRAM flap 31 
Pedicled LD flap +/- implant 18 
Free DIEP flap 7 
Free SIEA flap 2 
Implant only 1 
 
Oncological adjuvant therapy 
23 (38%) patients received secondary adjuvant oncological therapy following surgery of the IBTR. 
(Table 3) 
Table 3 Adjuvant therapy for locally recurrent breast cancer (Studies I and II) 
Adjuvant therapy for locally recurrent breast 
cancer 
Study I Study II 
n=23 (38%) n=35 (88%) 
Radiotherapy 0 2 
Radiotherapy, chemotherapy 0   4a 
Radiotherapy, hormonal therapy  0   1b 
Radiotherapy, chemo- hormonal therapy 1   3c 
Chemotherapy 3        17*d 
Chemo- hormonal therapy  12         2**e 
Hormonal therapy 7   6 
*3 cases neoadjuvant;  **1 case neoadjuvant; a 1 case palliative; b palliative; c 1 case palliative;          
d 3 cases palliative; e 1 case palliative 
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Complications and reoperations are shown in Table 4. There were no flap losses.   
Table 4. Complications and reoperations (Study I) 
 
Complications and reoperations Number of 
patients 
Reoperations 
 
Microvascular re-anastomosis                   
Wound infection debridement                   
Haematoma drainage                                      
Flap skin/ fat necrosis debridement +/-skin graft 
 
 
 
1             
1 
4 
3 
 Conservatively managed complications 
 
Flap related                                                             
Wound infection                                                        
Skin/ fat necrosis 
 
SSM                                                                                
Minor skin flap necrosis 
 
Donor site                                                                        
Seroma                                                                           
Minor abdominal wound edge necrosis 
 
General                                                                
Pulmonary embolism (mild symptoms) 
 
 
 
 
3 
2 
 
 
11 
 
 
2 
4 
 
 
2 
 
Disease relapse 
The median follow-up time after SSM and IBR was 84 months (range 14-190 months). 11 (18%) 
patients developed disease relapse and 49 (82%) patients remained disease-free. The median time 
interval to disease relapse was 40 months (range 6-64 months). Disease relapse consisted of 6 local 
re-recurrences (10%), 3 cases of regional lymph node metastasis and 2 cases of distant metastasis. 
4 of the 11 (7% overall) patients with disease relapse eventually died. 5 year OS was 94% and 5 year 
DFS was 83%.  
As many as 26 (43%) patients did not meet our selection criteria; but interestingly only 3 of these 
suffered a disease relapse (11.5%) compared to 8 (23.5%) of those who did meet the criteria. These 
2 groups were compared using a Chi-squared test and no significant difference (p=0.234) in 
disease relapse rates was found. The most common selection criteria not met were: recurrent 
tumour < 3cm, primarily node negative and recurrence more than 3 years after primary operation.  
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8.2 Study II 
The mean age at primary breast cancer diagnosis was 46 years (range 32-67 years). (Table 5) The 
median disease-free interval after primary treatment to first recurrence was 2.4 years (range 0.3-34 
years). Extensive chest wall recurrence was the first local relapse in less than half of the patients. 
Referral to our department for chest wall resection after failure of oncological therapy or earlier 
attempts at surgical excision elsewhere occurred in 25 patients. 
 
Table 5 Characteristics of primary tumour and chest wall recurrence (Study II) 
 
Primary breast cancer  n=40 Chest wall recurrence n=40 
 
Age at primary diagnosis 
<40 
>40 
 
28 
12 
Age (years) 
<60 
>60 
 
28 
12 
Primary tumour status 
T1 
T2 
T3 
T4 
Unknown 
 
15 
12 
5 
3 
5 
Interval to first recurrence (years) 
>2 years 
<2years 
 
 
21 
19 
 
Primary node status 
N0 
N>0 
Unknown 
 
 
17 
18 
5 
Total no. of recurrences 
1 
2 
3 
4 
5 
 
18 
11 
6 
4 
1 
Primary metastases 
Yes 
No 
Unknown 
 
1 
35 
4 
Earlier treatment of chest wall recurrence 
Excision 
Radiotherapy 
Chemotherapy 
Hormonal therapy 
 
16 
17 
15 
11 
Primary treatment 
BCT 
Mastectomy 
 
9 
31 
Distant metastasis  
Yes 
No 
 
4 
36 
Primary radiotherapy 
Yes 
No 
 
32 
8 
Ulceration 
Yes  
No 
 
13 
27 
Primary chemotherapy 
Yes 
No 
 
13 
27 
Inflammatory signs 
Yes 
No 
 
8 
32 
Primary hormonal therapy 
Yes 
No 
 
5 
35 
Intent of surgery 
Curative 
Palliative 
 
31 
9 
 
The mean age at surgery was 54 years (range 33-77 years). (Table 6) The mean size of en bloc 
resection was 303 cm² (range 35-1400 cm²). A mean of 3.1 ribs (range 2-7) were resected and 
complete/partial sternal resection was performed in 9 patients. The median length of post-
operative hospital stay was 10 days (range 3 - 28 days). The median intensive care stay was 6 days 
(range 2 – 10) for the FTCWR patients. Clear margins (R0) were achieved in 27 (68%) cases and 
bone infiltration of ribs and/or sternum was confirmed histologically in 19 cases. (Neo)adjuvant or 
palliative oncological therapy was administered to 35 patients following surgery. (Table 3) 
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Table 6. Surgical resection and chest wall reconstruction data (Study II) 
Surgical data 
 
Number of 
patients 
Resected specimen 
Soft tissue only 
Soft tissue and bone 
 
21 
19 
Resection defect size 
>150 cm² 
<150 cm² 
 
27 
13 
Chest wall stabilisation   
Yes 
No 
 
17 
23 
Method of chest stabilisation 
Synthetic mesh 
 Dacron  
 Prolene 
 Premilene  
 Gore-tex mesh  
 
Fascia lata  
Free rib grafts  
Dacron mesh and free rib graft 
 
 
7 
4 
1 
1 
 
2 
1 
1 
Soft tissue reconstruction 
Yes 
No 
 
40 
0 
Method of soft tissue reconstruction 
Pedicled flap (n=33)                                                              
 LD musculocutaneous flap 
 Bipedicled rectus abdominus 
musculocutaneous flap      
 Pectoralis major muscle flap                                 
 Scapular fasciocutaneous flap                              
 
Microvascular flap (n=7) 
 Tensor fascia lata +/- rectus femoris muscle 
flap                    
 LD musculocutaneous flap                                    
 TRAM flap         
 
 
 
29 
2 
 
1 
1 
 
 
4 
 
2 
1 
Radicality 
R0 
R1 
R2 
 
27 
3 
10 
Bone infiltration 
Yes 
No 
 
 
19 
21 
Notes: R0-complete resection with microscopically negative resection margins; R1-macroscopically 
complete resection but diseased microscopic margins; R2- macroscopic residual disease after 
attempted resection 
Complications  
 
There were no actual in-hospital deaths but 2 deaths occurred at 30 days due to medical 
complications after transfer to their local district hospital. There were neither any complete nor 
partial flap losses. (Table 7) 
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Table 7. Complications and reoperations (Study II) 
 
Complications and reoperations Number 
of 
patients 
Reoperations 
Re-excision for R1 resection 
Re-grafting of flap donor site 
 
 
1 
1 
Surgical complications (minor) 
Delayed flap donor site healing 
Flap donor site infection 
Donor site seroma 
 
 
3 
2 
1 
Medical complications 
Pneumonia 
Pulmonary embolism (mild) 
Pleural effusion 
Pneumothorax (small) 
 
 
2 
1 
1 
1 
 
Oncological outcome 
 
Median length of follow-up was 31 months (range 1 - 310). There were no patients lost at follow-up. 
23 patients suffered disease relapse and in 13 patients the first recurrence was a locoregional 
relapse. Six patients lived longer than 10 years.  
 
Outcome after resection with curative intent  
 
Tumour-free resection margins (R0) were achieved in 24/31(77%) patients. 20 patients however 
developed a relapse and half of these were locoregional. The median DFS after extensive resection 
was 31 months and the median OS was 52 months (95% CI 32 to 72 months). The 2 and 5 year OS 
rates were 71% and 32% respectively. 
 
Outcome after palliative resection 
 
Clear microscopic margins (R0) were achieved in 3/9 patients. The median OS after extensive 
resection was 17 months. Unsurprisingly patients who had palliative surgery had a statistically 
significant lower survival rate as compared to patients treated with a curative intent. There were 2 
locoregional relapses and 1 relapse in the ipsilateral LD flap donor site. This was subsequently 
treated with radiotherapy.  
 
Prognostic factors  
 
Patients aged less than 40 years at primary diagnosis and those with chest wall resections less than 
150cm² had a higher survival rate that was statistically significant on univariate analysis. 
Multivariate cox regression analysis revealed that only resection size was still statistically 
significant with a threefold increased risk of mortality for resections more than 150 cm². 
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8.3 Study III                                                                                                                                                            
The patient and tumour characteristics are provided in Table 8.                                                         
Table 8 Patient and tumour characteristics (Study III) 
   Immediate 
reconstruction 
(n=13) 
Delayed 
reconstruction 
(n=118) 
No 
reconstruction 
(n=391) 
Chi-
square P 
Age at mastectomy                   
<40 yrs                                                
40-55 yrs                                           
55-69 yrs 
                                  
2 (15%)                    
8 (62%)                   
3 (23%) 
                                      
29 (25%)                     
63 (53%)                     
26 (22%) 
                                   
13 (3%)                  
174 (45%)            
204 (52%) 
 
<0.0001 
Lymph node status                    
N0                                                    
N1                                                    
N2-3 
                                
10 (77%)                  
2 (15%)                    
1 (8%) 
                                      
47 (40%)                     
43 (36%)                     
28 (24%) 
                               
167 (43%)               
138 (35%)              
86 (22%) 
 
0.1562 
Histological T-stage                      
T1                                                         
T2                                                        
T3                                                        
T4                                                        
Not available 
                                
11 (84.6%)              
1 (7.7%)                   
1 (7.7%)                   
0 (0%) 
                                    
49 (42%)                     
59 (50%)                     
6 (5%)                          
3 (3%)                          
1 
                                  
192 (49%)                 
160 (41%)                  
27 (7%)                      
12 (3%) 
 
 
0.0821 
Histological grade                         
1                                                            
2                                                            
3                                                           
Not available 
                                
3 (23%)                   
7 (54%)                   
3 (23%) 
                                    
17 (14%)                      
45 (39%)                     
54 (47%)                     
2 
                                  
93 (24%)                   
167 (43%)                  
126 (33%)                 
5 
 
0.0423 
Histological type                   
Ductal                                        
Lobular                                         
Other                                                 
Not available 
                                
7 (54%)                   
3 (23%)                   
3 (23%) 
                                      
73 (62%)                     
34 (29%)                     
11 (9%) 
                                  
213 (55%)                  
112 (29%)                  
65 (16%)                    
1 
 
0.3106 
ER status                                
Positive                                      
Negative                                             
Not available 
                                
9 (75%)                   
3 (25%)                   
1 
                                    
96 (81%)                     
22 (19%) 
                                  
310 (80%)                 
78 (20%)                   
3 
 
0.8521 
PgR status                              
Positive                                   
Negative                                           
Not available 
                                  
8 (67%)                   
4 (33%)                   
1 
                                      
77 (65%)                      
41 (35%) 
                                   
228 (59%)                 
160 (41%)                  
3 
 
0.4086 
HER-2 status                      
Negative                                   
Positive                                            
Not assessed                                   
Not available 
                                
10 (100%)               
0                               
3 
                                    
86 (81%)                     
20 (19%)                     
12 
                                  
293 (83%)                 
58 (17%)                    
39                               
1 
 
0.3057 
MIB-1 proliferation index          
Negative or very low             
Medium                                         
High                                             
Not available 
                                
8 (80%)                   
0 (0%)                     
2 (20%)                   
3 
                                 
45 (47%)                     
22 (23%)                     
28 (30%)                     
23 
                              
176 (53%)                  
55 (17%)                    
98 (30%)                   
62 
 
 
0.213 
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Tumour multifocality                 
Yes                                                     
No                                                      
Not available 
                                
4 (31%)                    
9 (69%) 
                                    
39 (33%)                     
79 (67%) 
                                  
133 (34%)                 
256 (66%)                 
2 
 
0.9465 
Extensive intraductal 
component                                    
Yes                                                    
No 
                                
6 (46%)                   
7 (54%) 
                                    
27 (23%)                     
91 (77%) 
 
51(13%)                     
340 (87%) 
 
0.0004 
Axillary surgery                        
SLNB                                                
ALND                                                 
Both 
                                
4 (31%)                    
8 (62%)                   
1 (7%) 
                                    
16 (14%)                      
71 (60%)                     
31 (26%) 
                                  
48 (12%)                   
269 (69%)                 
74 (19%) 
 
0.0972 
Radiotherapy                 
Radiotherapy                                     
No radiotherapy                              
Thoracic wall only                          
Thoracic wall and regional nodes     
Regional nodes only 
                                
2 (15.4%)                
11 (84.6%)              
0                               
2 (15.4%)                
0 
                                    
76 (64.4%)                  
41 (35.6%)                  
13 (11.0%)                   
62 (52.5%)                  
1 (0.8%) 
                                  
230 (58.8%)             
159 (41.2%)               
45 (11.5%)                 
182 (46.5%)              
3 (0.8%) 
 
 
0.9476 
Systemic adjuvant therapy        
Chemotherapy                     
Endocrine therapy                     
Chemo- and endocrine therapy     
Chemotherapy and trastuzumab 
                                
2 (15.4%)                
0                               
3 (23.1%)                
0 
                                    
20 (16.9%)                  
15 (12.7%)                   
72 (61%)                      
2 (1.7%) 
                                  
69 (17.6%)                
91 (23.3%)                
165 (42.2%)              
3 (0.8%) 
 
 
0.0354 
Events                                            
LRR                                       
Contralateral cancer                 
Distant metastasis                     
Deaths, breast cancer                  
Deaths, other                              
Deaths, unknown cause 
                                  
3 (23.1%)                
0                               
0                               
0                               
0                               
0 
                                      
1 (0.8%)                      
4 (3.4%)                      
16 (13.6%)                   
3 (2.5%)                      
0                                   
0 
                                  
21 (5.4%)                  
26 (6.6%)                  
84 (21.5%)                
63 (16.1%)                 
21 (5.4%)                   
4 (1%) 
                  
0.1151    
0.0566 
0.006 
0.0000 
0.0256 
0.5092 
Abbreviations: ER=oestrogen receptor, PgR=progesterone receptor, HER2=human epidermal 
growth factor receptor-2. MIB-1=an antibody against Ki-67, SLNB=sentinel lymph node biopsy, 
ALND=axillary lymph node dissection  
 
Reconstruction patients were younger, more frequently had EIC and a grade 3 tumour. Other 
potential prognostic/risk factors were similar between the reconstruction and mastectomy only 
patient groups (Table 8).  
4 LRRs occurred in patients who underwent reconstruction (3.1%) and 21 LRRs occurred in 
patients treated with mastectomy only (5.4%), (P=0.1151, Chi square). The median time from 
primary surgery to LRR was 22 months (range 5-28 months) in the reconstruction group and 15 
months (range 1-21 months) in the mastectomy only group. Three LRRs (2 mastectomy scar 
recurrences and 1 axillary recurrence) followed immediate reconstruction with free TRAM flap 
(n=1) and LD flap (n=2) at 5, 22 and 28 months after surgery. The only local recurrence in the 
delayed reconstruction group occurred 6 years prior to implant reconstruction. Therefore this 
patient was excluded from further statistical analyses. 
Distant metastases were observed in 100 (19.2%) patients. No distant metastases occurred in 
patients with immediate reconstruction. Distant disease was diagnosed in 16 (13.6%) cases 
following delayed reconstruction and in 84 (21.5%) cases following mastectomy alone (P=0.006, 
Chi square).  
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Three (2.5%) patients died of breast cancer following reconstruction and 63 (16.1%) patients died 
following mastectomy alone (P=0.000003, Chi square).  There were no deaths in the immediate 
reconstruction group from any cause. The cause of death was unknown or other than breast cancer 
in 25 (6.4%) patients. The 8-year BCSS was 88.7% and OS 84.1% for the entire study population. 
Reconstruction status as a risk factor for LRR, DM, BCSS and OS 
The 8-year LRR rate was 5.4% in the mastectomy only group, 0.8% in the delayed reconstruction 
group and 23.1% in the immediate reconstruction group. (P=0.001, log rank). Cox multivariate 
analysis revealed immediate reconstruction (HR 6.339; 95% CI 1.814-22.151, P=0.004) to be an 
independent risk factor for LRR. 
Patients who had a reconstruction had a lower 8 year rate of DM (9.2%), when compared to 
patients without reconstruction (19.9%) (P=0.010, log rank). Cox multivariate analysis revealed no 
reconstruction (HR 2.212; 95% CI 1.170-4.202, P=0.015) to be an independent risk factor for DM. 
In patients with no reconstruction the 8-year BCSS and OS were 85.7% and 79.5% respectively 
while these were both 98.5% in patients who had a reconstruction, log-rank P=0.000. In 
multivariate analysis no reconstruction was an independent risk factor for both poor BCSS (HR 
20.408; 95%CI 2.778-142.857, P=0.003) and poor OS (HR 28.571; 95%CI 3.968-200, P=0.001). 
Outcome of patients without early distant recurrences 
The median time from mastectomy to delayed reconstruction was 34 months due to strict selection 
criteria as well as long waiting times. As delayed reconstruction was not offered to patients with 
early distant recurrence we decided to exclude all patients who developed distant metastases 
within 48 months of primary surgery in an attempt to compensate for this selection bias. The rate 
of distant metastasis now became similar between the reconstruction and no reconstruction groups 
(P=0.613, log rank). However the reconstruction group still had statistically significant superior 
BCSS (P=0.028) and OS (P=0.000). 
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8.4 Study IV  
Angiosarcoma (AS) was diagnosed a median of 5.25 years (range 3.8-12.25 years) following RT. 
Median age at diagnosis of AS was 60 years (range 46-84 years). In 6 cases there was an apparent 
delay in establishing the diagnosis of AS. All patients presented with a reddish-purplish or 
ecchymosed lesion in the skin.  
All AS lesions arose in the centre of the previously administered radiation fields. One exception was 
1 patient who presented with a synchronous 3cm AS lesion in the lower pole of the normal 
contralateral breast. 
All patients except one, underwent excision with a curative intent with a minimum clinical lateral 
margin of 3 cm. The exception was a case initially operated on in another hospital with a less 
radical resection and subsequently presented to us with widespread multiple lesions. For the 
remaining 9 patients however the surgical procedure consisted of radical mastectomy (n=5), simple 
mastectomy (n=2), wide local excision (n=1) and TRAM flap excision and wide local excision (n=1). 
Marked lateral and deep excision margins are shown in Table 9. 
 
Table 9 Macroscopic excision margins for angiosarcoma (Study IV) 
Macroscopic marked excision margins Number of patients 
Lateral surgical margins 
 >3cm 
 4-5cm 
 
4 
5 
Deep excision margins 
 removing pectoralis major muscle fascia     
 removing pectoralis muscle   
 removing both pectoralis major & minor muscles    
 
3 
5 
1 
 
The post-excision defect was directly closed in 2 cases or reconstructed using a pedicled 
musculocutaneous LD flap (n=4) or split-thickness skin graft (n=4).  
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Figure 4 Wide resection of left breast AS and reconstruction with LD flap and skin graft 
 
 
Following surgery there were no reported wound healing complications. Six cases were classified as 
high grade AS and all specimens underwent immunohistochemical analysis for factor VIII antigen, 
CD34 and CD31 markers.  Clear histological margins were achieved in all cases. Wide histological 
margins (> 2cm) were recorded in eight cases and a marginal excision (< 2cm) recorded in two 
cases. 
Oncological outcome 
Median follow-up was 81 months (range 4-143 months). 3 patients suffered a recurrence. Two of 
these were local skin recurrences (1 and 3 months following surgery) and the other was a distant 
skin recurrence to the contralateral breast (37 months following surgery). One of the two local 
recurrences was initially treated by an extended course of chemotherapy and later by palliative 
surgical resection. She eventually died from disseminated AS disease. Surgical resection was 
planned for the other case of local recurrence but the patient was medically unfit for surgery and 
consequently managed palliatively. She died one month later from disseminated disease. The case 
of a distant recurrence in the contralateral breast followed earlier treatment for stage 1 primary 
breast cancer (mastectomy, axillary clearance but no adjuvant radiotherapy). This recurrence was 
treated by wide local excision and the patient was alive and disease-free at the end of the study 
period. 7 patients were alive and disease-free at the end of the study period. 3 patients died at 4, 8 
and 13 months following surgery. 2 of these died from disseminated AS. The other case died from 
an unrelated cause. 5 year overall survival was 70%. 
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9. DISCUSSION 
 
9.1 Management of locally recurrent breast cancer 
Locoregional breast cancer recurrence is a heterogeneous disease entity that encompasses small 
ipsilateral breast tumour recurrences following primary breast conserving surgery as well as 
extensive chest wall recurrences following mastectomy occurring in the skin, subcutaneous tissue 
or musculoskeletal chest wall with or without regional nodal metastases. Patients with a local 
relapse after primary breast cancer surgery tend to have a poor prognosis (Abner et al.1993; Courdi 
A et al. 2006 Fodor et al. 2008). At present no standard guidelines exist for the management of a 
locally recurrent tumour. This is coupled with a lack of good clinical trials that would provide 
evidence in support of a more specific management rationale.  
For an IBTR most would agree that salvage mastectomy is most appropriate (Chen and Martinez. 
2008) and in exceptional cases a re-lumpectomy is possible (Ishitobi et al. 2011). In Helsinki we 
opt in nearly all cases for a salvage mastectomy for a local recurrence following breast conserving 
surgery. Immediate breast reconstruction is possible in those selected cases considered to have a 
good prognosis. In study I our follow-up time was fairly short but our local re-recurrence rate of 
10% compares well with that following salvage mastectomy for locally recurrent breast cancer 
(Dalberg et al. 1998; Chen and Martinez. 2008). Our 5 year overall survival was 94% which 
compares very well with other reported figures of around 60-70% after treatment for IBTR 
(Clemons et al. 2001). Our 5 year disease free survival was 83% which also compares extremely 
well with long term reported rates of only 30-50% (Haffty et al. 1996; van Tienhoven et al.1999). Of 
course our markedly superior rates can be accounted for by the fact that our subset of IBTR 
patients were highly selected as those having a better prognosis. The introduction of new 
oncological treatment modalities since those older studies were performed is another possible 
contributory factor. However the good survival figures in our series show that IBR was offered to 
women who could recover and benefit from the breast reconstruction. 
Our selection criteria were originally intended to select those patients considered to have a more 
favourable prognosis; this was mainly in view of then limited resources. As many as 26 (43%) 
patients did not ultimately meet our selection criteria but these patients seemed to fare comparably 
well to those who did meet the criteria. This suggests that we should perhaps widen our selection 
criteria or use other predictive factors that may better identify patients at risk of further recurrence. 
In our patient series it appeared that a recurrent tumour > 3cm, primarily node positive or a 
recurrence less than 3 years after primary operation were risk factors that did not necessarily 
predict a poorer outlook. Positron emission tomography-computed tomography (PET-CT) is 
increasingly being used in tumour surveillance. It could perhaps have a valuable role to play in 
selecting those patients with IBTR who are most appropriate for SSM and IBR by improved staging 
of the local recurrence and exclusion of distant disease (Radan et al. 2006). 
In addition should one attempt to classify a local recurrence as a new primary tumour, a true 
recurrence or as persistence of disease? Each of these would then maybe require a slightly different 
management strategy as for example new primary tumours are associated with a better prognosis 
than a true recurrence (Veronesi et al. 1995; Huang et al. 2002; Nishimura et al.2005). 
There is an ongoing debate as to whether IBTR is a cause of later distant metastases (Halstedian 
paradigm) or merely reflects tumour biology and is a manifestation of risk of distant relapse 
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(Fisherian paradigm). The Halstedian paradigm describes the sequential spread of breast cancer 
from a single focus within the breast and that lymph node involvement is necessary for 
haematogenous dissemination. In contrast the Fisherian paradigm states that the spread of tumour 
cells into the bloodstream occurs early in tumourigenesis and precedes lymph node infiltration. In 
any case local recurrence within a conserved breast is the single most important predictor of overall 
survival (Benson and Querci della Rovere. 2008).  
Whereas there is general agreement that IBTR is potentially curable by surgery and secondary 
adjuvant therapy (when indicated); the same cannot be said for patients with a more extensive 
chest wall recurrence. These patients tend to have a poor prognosis and therefore there is some 
debate over the cost effectiveness of pursuing a curative approach in all cases. In fact in many 
institutions surgery is probably not the first line option taken. This notwithstanding the potential 
benefits of palliative surgery should be emphasized. 
Extensive chest wall resections should aim to achieve local control, improve survival and/or 
provide good palliation with low morbidity and mortality. Reconstruction is then necessary to 
cover exposed vital structures, bring about timely wound closure and avoid delay in the 
administration of adjuvant therapy. Several series have demonstrated the safety of full-thickness 
chest wall resection (Arnold and Pairolero. 1996; Cohen and Ramasastry. 1996; Faneyte et al. 1997; 
Toi et al. 1997; Tukiainen et al. 2003; Chang et al.  2004; Losken et al. 2004; Pameijer et al. 2005). 
Our operative mortality rate of 5% is acceptable in comparison. (Operative mortality was defined as 
any death occurring within 30 days after surgery in or out of the hospital). 
If bone or cartilage is exposed following resection then a flap of vascularised tissue is required to 
cover the defect. In cases of full-thickness defects of the bony chest wall with exposure of the vital 
structures, depending on anatomical location and defect size, some form of chest wall stabilisation 
may be required. Large anterior and antero-lateral thoracic wall defects usually require 
stabilisation to prevent flail chest (or lung herniation) and paradoxical breathing and to protect the 
underlying lungs and/or heart (Arnold and Pairolero. 1996; Cohen and Ramasastry. 1996; Chang et 
al.  2004; Losken et al. 2004). A synthetic mesh is most commonly employed. We tend to always 
use mesh stabilisation for defects up to 10 by 10 cm in size. For larger defects we include a rib graft 
or cement to further increase stability. We have found the critical areas in terms of flail movement 
risk to be the pleural dome area after extended forequarter amputation with rib resections and the 
sternal area. Following chest wall stabilisation a vascularised flap reconstruction is then required to 
provide a water and air tight closure of the chest cavity, control infection, obliterate dead space, 
cover the synthetic material and close the soft-tissue defect (Losken et al. 2004).  
Several options for flap reconstruction exist. In our protocol we prefer to use a pedicled flap when 
possible; usually the pedicled latissimus dorsi flap when available due to its proximity to the defect, 
ease of mobilisation, large size and reliable pedicle. Other pedicled flap options include the 
pectoralis major muscle and VRAM flaps. Microvascular flaps may sometimes be necessary if local 
muscle flaps are unavailable or insufficient in size. We frequently use the free tensor fascia lata 
(TFL) or extended TFL musculocutaneous flap as this can provide a very large flap and allow a 2 
team approach. The inclusion of the rectus femoris muscle enables an even larger flap with extra 
bulk to be harvested (Tukiainen et al. 2003). The TFL flap is also advantageous when considering 
donor site morbidity as there is minimal interference with respiratory function in contrast to other 
flap options from the thoraco-abdominal area. Other free flap options that we consider include the 
anterolateral thigh (ALT) and TRAM flaps. Occasionally we might use the omentum flap or breast 
flap. The use of flap reconstruction enables radical resections with wide excision margins.   
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The median disease-free interval after extensive resection for curative intent in our series was 2.5 
years which compares well to a recent report by Aukema et al whose group recorded a 2 year 
median disease-free survival (Aukema et al. 2009). Overall survival rates vary widely between 
different published series and our 5 year survival rate of 32% is to the lower end of published 5 year 
survival rates that range from of 18% to 71% (Faneyte et al. 1997; Toi et al. 1997; Downey et al. 
2000; Chagpar et al. 2003; Pameijer et al. 2005; Friedel et al. 2008; van der Pol et al. 2009; Noble 
et al. 2010). Patient selection and the fact that all our cases had extensive recurrences may partly 
account for our lower comparative survival rate. Also our study covers a long time period in which 
treatment modalities have changed and staging improved with the use of better quality CT imaging 
in recent years. A R0 resection was achieved in 68% of our cases which is similar to previous 
reports (Pameijer et al. 2005; Friedel et al. 2008; van der Pol et al. 2009). 
Palliative surgery can be indicated for several reasons such as pain, haemorrhage, large 
malodorous ulceration, recurrent infection and local control of the disease. Quality of life benefits 
have been highlighted in a recent study (Veronesi et al. 2007). Our median survival of 1.4 years 
after palliative surgery compares well with other reports (Veronesi et al. 2007; Aukema et al. 
2009). Only one third of these patients developed a local relapse. Furthermore many patients were 
very satisfied after surgery as they could now re-engage socially with family and friends. 
Surgery may also have a useful role to play when oncological therapy cannot be continued due to 
extensive tumour ulceration. In this scenario radical resection and wound closure with a flap 
facilitates the provision of further oncological therapy. 
A few studies have assessed the impact of prognostic factors on survival after chest wall recurrence 
(Faneyte et al. 1997; Chagpar et al. 2003; Pameijer et al. 2005; Friedel et al. 2008; van der Pol et al. 
2009). In our study patients aged less than 40 years at primary diagnosis and those with chest wall 
resections less than 150cm² had a statistically significant higher survival rate on univariate 
analysis. Only resection size remained significant on multivariate analysis.  
Our patients had extensive recurrences and in the majority of cases multiple earlier recurrences or 
unsuccessful oncological therapy. In spite of this we have achieved reasonable local control and 
overall survival through surgical intervention. A multidisciplinary approach should be emphasised 
with early consultation of the plastic surgeon. Patient selection is however critical and should be 
individualised with thorough pre-operative assessment of the possible benefits of surgery weighed 
against the risks. Two groups of patients appear to benefit the most from surgery. Curative 
resection and prolonged survival is possible in patients with a small chest wall recurrent tumour 
and palliative surgery should be considered in patients for whom quality of life issues are of 
paramount importance and social re-integration should be the aim of surgery.  
The management of locally recurrent breast cancer should be multimodal with a multidisciplinary 
approach. The close co-operation of surgeons and oncologists is vital. The precise role of adjuvant 
therapy after surgery for both IBTR and chest wall recurrent breast cancer is unclear, but one must 
consider patients with any indicators for poor prognosis as described earlier. It may therefore be 
appropriate to administer adjuvant therapy to those patients with clearly defined risk factors for 
disease relapse (Sirohi et al. 2009).  
We have analysed the results of reconstructive surgery in the setting of a locally recurrent breast 
cancer but maybe we should consider further the possibilities of preventing LRR. Following a 
diagnosis of primary breast cancer one should carefully plan, ideally in a multidisciplinary team, 
the appropriate management. The extent of surgery should be tailored to the 3 dimensional 
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features of the primary tumour and possible DCIS with the help of suitable imaging and 
preoperative histology in order to enable complete excision with sufficient margins and ultimately 
choosing between mastectomy and BCT. The importance of radiotherapy in improving prognosis 
has been re-appraised (Clarke et al. 2005; Darby et al. 2011).   
 
9.2 The impact of breast reconstruction on oncological outcome 
Breast reconstruction is now a fundamental part of the overall management of patients with breast 
cancer. Numerous studies have reported very low recurrence rates following immediate and 
delayed breast reconstruction (Nieminen et al. 1999; Meretoja et al. 2007; Vaughan et al. 2007; 
McCarthy et al. 2008; Yi et al. 2011; Patterson et al. 2012). However in most studies a mastectomy 
only control group has been lacking.  
A recent Swedish study by Isern et al. reported a higher rate of local and distant recurrences after 
delayed reconstruction when compared to mastectomy alone in a matched cohort of patients. This 
study comprised of only delayed flap reconstructions, all of which were pedicled or microvascular 
flaps (Isern et al. 2011). There have been a few studies that discuss the somewhat contentious 
possibility of surgery-driven enhancement of metastasis (Demicheli et al. 2008). Thus could the 
additional surgery of a major autologous reconstruction pose a risk in some patients? Our study 
consisted of mostly delayed autologous flap reconstructions and in contrast showed that breast 
reconstruction does not increase the DM rate nor worsen survival. This is also in agreement with 
several other studies (McCarthy et al. 2008; Eriksen et al. 2011; Nedumpara et al. 2011; Reddy et 
al. 2011; Agarwal et al. 2012). When considering free autologous reconstructions we recorded only 
one LR and 7 DMs following 63 microsurgical breast reconstructions. Similarly low LR and LLR 
rates have been reported following free TRAM flap reconstructions (Nieminen et al. 1999; 
Patterson et al. 2012). A possible explanation for the contradictory results of our study and the 
Swedish study lies in the different study settings. We had a slightly shorter follow-up time (median 
102 months versus 146 months), although our DM rate does not appear to accelerate with time 
after reconstruction. Additionally the Swedish study involved patients operated primarily in ten 
different hospitals and the reconstructive surgery was performed between 1982 and 2001. Our 
series was a single institution experience from more recent times.  
We found a higher rate of LRR after IBR than previously reported in other studies (Vaughan et al. 
2007; McCarthy et al. 2008; Yi et al. 2011; Patterson et al. 2012). In nearly all our immediate cases 
a skin-sparing mastectomy (SSM) was performed and this group also had a higher frequency of 
extensive intraductal component. In addition mastectomy margins were not routinely assessed by a 
histopathologist during the study period. It is therefore possible that some breast tissue may have 
been left behind in the skin flaps of the SSM. Previous studies have reported the finding of residual 
breast tissue in the skin after SSM in up to 9.5% of cases (Torresan et al. 2005; Dreadin et al. 
2012). This was associated with skin flaps greater than 5 mm thick (Torresan et al. 2005) but with 
no detrimental effect on oncological outcome (Dreadin et al. 2012). Our IBR group was however 
very small (n=13, 2 LR and 1 LRR) due to the fact that the main indication for immediate 
reconstruction was extensive DCIS as the pre-operative diagnosis. A larger series of IBRs from our 
unit has been published and the rate of LRR was 5.8% in patients with stage 0-2 disease and 31% in 
women with stage 3 disease after a mean follow-up of 70 months (Meretoja et al. 2007). Thus it is 
difficult to draw reliable conclusions from our results. A recent meta-analysis demonstrated no 
evidence for increased LR with IBR compared with mastectomy alone (Gieni et al. 2012). 
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In order to compensate for selection bias we excluded patients with an early distant recurrence. 
This resulted in a similar DM rate between the reconstruction and no reconstruction groups but 
BCSS and OS remained superior in reconstruction patients. This could be due to the fact that 
patients selected for reconstruction were younger and most likely had less severe co-morbidities. 
Patients with poorer general health may not be fit enough for chemotherapy which in turn may 
result in a poorer BCSS as well as an inferior OS. 
In summary the strengths of study III were the presence of a control group and a reasonable 
follow-up time but the main limitations included the lack of randomization and being retrospective 
in nature. No prospective randomized trials comparing mastectomy with or without breast 
reconstruction have been published. This can be attributed to several factors: ethical reasons, the 
need for individualized therapies and unique patient anatomy. Therefore randomization would be 
almost impossible.  
 
9.4 Surgical management and oncological outcome of radiation-associated breast 
angiosarcoma 
In addition to the risk of breast cancer relapse there is another threat to the survival of the patient 
following treatment of the primary disease. Of those patients who have received radiotherapy 
around 0.05% will develop an aggressive secondary breast/ chest wall soft-tissue sarcoma which is 
associated with a poor prognosis: angiosarcoma (Marchal et al. 1999). This entity was first reported 
by Stewart and Treves in 1948 as a consequence of upper extremity chronic lymphoedema 
following mastectomy and axillary clearance (Stewart and Treves. 1948). 
All the cases of AS in our series were diagnosed during the last 10 years which may reflect the 
increasing use of RT in breast cancer management. Every case developed in the centre of the 
radiation field which correlates with the area receiving the full prescribed radiation dose of 50 Gy. 
The median latency period for the development of AS in our study was 5 years. This is comparable 
to other studies (2-9 years), and shorter than the traditional latency period for other RT induced 
sarcomas of more than 10 years (Fineberg and Rosen. 1994; Strobbe et al. 1998; Monroe et al. 
2003; Hodgson et al. 2007; Feigenberg et al. 2002; Seinen et al. 2012; Hui et al. 2012; Morgan et 
al. 2012; Jallali et al. 2012). A recent study shows that the risk of AS only decreases to the normal 
non-RT risk after 20 years (Mery et al. 2009). 
We saw two bilateral cases of breast AS and very few bilateral cases have been reported in the 
literature. One case consisted of a synchronous AS occurring in the contralateral previously normal 
non-irradiated breast and the other case consisted of a metachronous tumour occurring in the 
contralateral breast previously treated for breast cancer but without RT. This suggests the 
possibility of another contributing, maybe genetic, factor (de Bree et al. 2002; West et al. 2012). 
Early diagnosis of AS is essential due to its aggressive course. We observed difficulty in making an 
early diagnosis of AS and this may be due to several reasons; lack of awareness of this rare 
condition, non-specific clinical signs with often benign-looking lesions. Additionally the 
histological diagnosis of AS may not always be straightforward (Fineberg and Rosen. 1994). Thus 
clinicians need to be vigilant with regards to the possibility of AS in breast cancer patients earlier 
treated with radiotherapy. Thorough physical examination and prompt multiple punch biopsies are 
essential. Other investigations such as mammography and MRI play only a limited role in 
diagnosing AS (Monroe et al. 2003; West et al. 2005; Hodgson et al. 2007). 
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The main treatment modality is surgery in the form of a wide excision that usually encompasses a 
simple/radical mastectomy (Strobbe et al. 1998; Marchal et al. 1999; Feigenberg et al. 2002; 
Monroe et al. 2003; Billings et al. 2004; Cha et al. 2004; Vorburger et al. 2005; West et al. 2005; 
Hodgson et al. 2007; Biswas et al. 2009; Young et al. 2010; Hui et al. 2012; Morgan et al. 2012; 
Seinen et al. 2012; Jallali et al. 2012). Regional lymph node involvement is uncommon either at 
presentation or at recurrence; hence routine axillary lymph node dissection is not indicated 
(Monroe et al. 2003). Based on the results of our study we recommend performing the resection 
with macroscopic lateral margins greater than 3cm, preferably 4-5 cm and deep margins including 
at least the pectoralis fascia. We achieved wide (>2cm) histological margins in all but one case. One 
recent report noted that incomplete excisions in their series usually involved the deep margin when 
pectoralis major muscle was not included (Jallali et al. 2012) and another report emphasized the 
need for radical removal of both pectoralis major and minor muscles (Hui et al. 2012). The extent 
of the irradiated field should also be considered when planning the surgical margin widths and 
another recent study recommended resection of all at-risk irradiated breast skin (Morgan et al. 
2012). There is an argument for deferring immediate flap reconstruction until a later date due to 
high rates of local recurrence. The post-excision defect can then be satisfactorily covered with a 
split-thickness skin graft in the interim. However we now tend to cover the defect immediately with 
a pedicled LD flap instead of grafting. Other recent reports have similarly described the use of flaps 
for immediate closure (Hui et al. 2012; Jallali et al. 2012). 
Seven patients were alive and disease-free at the end of the study period (median follow-up 81 
months). In comparison with other studies that report very poor overall survival, our experience 
has been more encouraging (Marchal et al. 1999; Monroe et al. 2003; Billings et al. 2004; Cha et al. 
2004; Hodgson et al. 2007; Hui et al. 2012; Seinen et al. 2012; Jallali et al. 2012). 
We are likely to see the incidence of AS rise as more women are treated by BCT for early stage 
breast cancer. Consequently, education of the patient, general practitioner, oncologist and surgeon 
is necessary to raise awareness of this condition. Although routine follow-up for breast cancer is 5 
years in many centres we would recommend surveillance for up to 20 years following RT.  
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10.  CONCLUSIONS 
 
I  Skin-sparing mastectomy and immediate breast reconstruction is a feasible treatment 
option for selected patients who develop a local recurrence following earlier breast 
conserving therapy. 
 
     II In selected patients autologous flap reconstruction enables the resection of extensive 
chest wall recurrent breast tumours with acceptable morbidity and reasonable local 
control and survival. Palliative surgery can also be invaluable to improve the quality 
of life in patients with extensive symptomatic recurrences.   
 
  
    III Breast reconstruction does not appear to adversely influence disease progression in 
forms of locoregional recurrences or distant metastases when compared to patients 
treated with mastectomy only. 
 
    IV Early diagnosis and excision with wide macroscopic margins is vital in improving 
survival in cases of radiation-associated angiosarcoma 
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